Methods and apparatus for treating embolism

Information

  • Patent Grant
  • 11648028
  • Patent Number
    11,648,028
  • Date Filed
    Friday, June 26, 2020
    4 years ago
  • Date Issued
    Tuesday, May 16, 2023
    a year ago
Abstract
A method and apparatus for treating a clot in the blood vessel of a patient, and particularly the treatment of a pulmonary embolism is disclosed. The treatment includes restoring flow through the clot followed by clot removal, either partially or substantially completely. The clot treatment device is expandable into the blood vessel and may contain radial extensions that assist in restoring flow as well as in removing clot material.
Description
TECHNICAL FIELD

This invention relates to the apparatus and methods of endovascular treatment of blood clots obstructing passageways in the circulatory system and particularly the endovascular treatment of pulmonary embolism.


BACKGROUND

Thromboembolism is the formation in a blood vessel of a clot (thrombus) that breaks loose (embolizes) and is carried by the blood stream to another location in the circulatory system resulting in a clot or obstruction at that new location. For example, a clot may embolize and plug a vessel in the lungs (pulmonary embolism), the brain (stroke), the gastrointestinal tract, the kidneys, or the legs. Thromboembolism is a significant cause of morbidity (disease) and mortality (death), especially in adults. A thromboembolism can be sudden and massive or it may be small and multiple. A thromboembolism can be any size and a thromboembolic event can happen at any time.


When a thrombus forms in the venous circulation of the body it often embolizes to the lungs. Such a thrombus typically embolizes from the veins of the legs, pelvis, or inferior vena cava and travels to the right heart cavities and then into the pulmonary arteries thus resulting in a pulmonary embolism.


A pulmonary embolism results in right heart failure and decreased blood flow through the lungs with subsequent decreased oxygenation of the lungs, heart and the rest of the body. More specifically, when such a thrombus enters the pulmonary arteries, obstruction and spasm of the different arteries of the lung occurs which further decreases blood flow and gaseous exchange through the lung tissue resulting in pulmonary edema. All of these factors decrease the oxygen in the blood in the left heart. As a result, the oxygenated blood supplied by the coronary arteries to the musculature of both the left and right heart is insufficient for proper contractions of the muscle which further decreases the entire oxygenated blood flow to the rest of the body. This often leads to heart dysfunction and specifically right ventricle dysfunction.


This condition is relatively common and has many causes. Some of the more common causes are prolonged inactivity such as bed rest, extended sitting (e.g., lengthy aircraft travel), dehydration, extensive surgery or protracted disease. Almost all of these causes are characterized by the blood of the inferior peripheral major circulatory system coagulating to varying degrees and resulting in permanent drainage problems.


There exist a number of approaches to treating thromboembolism and particularly pulmonary embolism. Some of those approaches include the use of anticoagulants, thrombolytics and endovascular attempts at removal of the emboli from the pulmonary artery. The endovascular attempts often rely on catheterization of the affected vessels and application of chemical or mechanical agents or both to disintegrate the clot. Invasive surgical intervention in which the emboli is removed by accessing the chest cavity, opening the embolized pulmonary artery and/or its branches and removing the clot is also possible.


The prior approaches to treatment, however, are lacking. For example, the use of agents such as anticoagulants and/or thrombolytics to reduce or remove a pulmonary embolism typically takes a prolonged period of time, e.g., hours and even days, before the treatment is effective. In some instances, such agents can cause hemorrhage in a patient. Moreover, the known mechanical devices for removing an embolism are typically highly complex, prone to cause undue trauma to the vessel, and can be difficult and expensive to manufacture.


Lastly, the known treatment methods do not emphasize sufficiently the goal of urgently restoring blood flow through the thrombus once the thrombus has been identified. In other words, the known methods focus primarily and firstly on overall clot reduction and removal instead of first focusing on relief of the acute blockage condition followed then by the goal of clot reduction and removal. Hence, known methods are not providing optimal patient care, particularly as such care relates to treatment of a pulmonary embolism.


SUMMARY

In view of the foregoing, several embodiments of the present technology to provide a method and system that initially restores an acceptable level of oxygenated blood to the patient's circulatory system followed by safe and effective removal of the thrombus.


Several embodiments of the present technology treat pulmonary embolism in a minimally invasive manner.


Several embodiments of the present technology can also provide a system that does not cause undue trauma to the vessel.





BRIEF DESCRIPTION OF THE DRAWINGS

These and other objects, aspects, features and advantages of which the present technology is capable will be apparent from the following description of embodiments of the present technology, reference being made to the accompanying drawings, in which



FIG. 1A is a schematic view of a patient with a pulmonary embolism;



FIG. 1B is an enlarged view of the lung area of the patient depicted in FIG. 1A;



FIG. 1C is an enlarged view of the introducer device depicted being used in the femoral vein of the patient in FIG. 1A;



FIG. 2 is a cross-sectional view of a patient's heart;



FIG. 3 is a perspective view of a patient's main pulmonary artery and right and left pulmonary arteries with a clot located in the left pulmonary artery;



FIG. 4 is a cross-sectional view of an embodiment of a clot treatment device in accordance with the present technology in a compressed, undeployed state;



FIG. 5A is a side cross-sectional view of a clot treatment device in a compressed, undeployed state within a delivery catheter in accordance with the present technology;



FIG. 58 is a top view of a clot treatment device in a deployed state in accordance with the present technology;



FIGS. 6A-6F are a series of cross-sectional views of embodiments of the method and device of the present technology;



FIGS. 7A-7B are a series of cross-sectional views of embodiments of the method and device of the present technology;



FIG. 8 is a cross-sectional view of another embodiment of the method and device of the present technology; and,



FIGS. 9A-9H show cross-sectional views of embodiments of a clot treatment device in accordance with the present technology.



FIG. 10 is a cross-sectional view of a clot treatment device in accordance with another embodiment of the present technology.



FIGS. 11 and 12 are detailed cross-sectional views of a distal portion and a proximal portion, respectively, of an expandable member of a clot treatment device in accordance with an embodiment of the present technology.



FIGS. 13 and 14 are detailed cross-sectional views of a proximal portion and a distal portion, respectively, of an expandable member of a clot treatment device in accordance with another embodiment of the technology.



FIGS. 15-18 are side views of guide catheters for use with clot treatment devices and methods in accordance with embodiments of the present technology.



FIG. 19 is a side view of a clot treatment device including arcuate clot engagement members configured in accordance with an embodiment of the present technology.



FIGS. 20-23 show embodiments of arcuate clot engagement members configured in accordance with the present technology.



FIGS. 24-25 are side views of clot treatment devices configured in accordance with embodiments of the present technology.



FIG. 26 is a circumferential structure including arcuate clot engagement members in accordance with embodiments of the present technology.



FIG. 27 is a side view of a clot treatment device having a distal radially extending member configured in accordance with another embodiment of the present technology.





DETAILED DESCRIPTION

Specific embodiments of the present technology will now be described with reference to the accompanying drawings. This present technology may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the present technology to those skilled in the art. The terminology used in the detailed description of the embodiments illustrated in the accompanying drawings is not intended to be limiting of the present technology. In the drawings, like numbers refer to like elements.


Referring to FIGS. 1A-1C, these drawings show the typical locations in a human patient where clots 100, such as pulmonary embolisms, thromboses, or other obstructions, occur in the pulmonary arteries and further discloses the pathway through which access to such clots 100 is achieved. In particular, an introducer device (e.g., a hemostatic valve) 102 which supports relatively large diameter devices is inserted into the patient into the femoral vein FV in the pelvic area of the patient. The tools and devices needed to treat the pulmonary embolism are then inserted through the introducer 102 into the femoral vein FV through the inferior vena cava IVC to the patient's heart.


It will be understood, however, that other access locations into the venous circulatory system of a patient are possible and which are consistent with the present technology. For example, the user can gain access through the jugular vein, the subclavian vein, the brachial vein or any other vein that connects or eventually leads to the superior vena cava. Use of other vessels that are closer to right atrium RA of the patient's heart may be attractive as this will reduce the length of the instruments needed to reach the pulmonary embolism.


Referring to FIGS. 2 and 3, the tools/devices are then guided through the right atrium RA through the tricuspid valve TV, into the right ventricle RV, through the pulmonary valve PV into the main pulmonary artery (MPA). Depending on the location of the embolism 100, the tools/devices are then guided to one or more of the branches of the right pulmonary artery RPA or the left pulmonary artery LPA, including deeper branches thereof, to the location of the pulmonary embolism 100.


Referring to FIG. 4, an embodiment of a clot treatment device 402 for restoring blood flow through the clot 100 and for removing at least a portion of the clot is depicted in its undeployed, or compressed state. The device 402 is constrained by a delivery catheter 606. In many embodiments, the device 402 comprises a braided material having ends that are captured distally by a tip 405 and proximally by an attachment member 403 that connects to a wire 401 configured to push and/or pull the clot treatment device 402.


In alternative embodiments, the clot treatment device 402 may be an “over the wire” device, in which case, the wire 401 is a tube or coil having a lumen, and the attachment member 403 and the tip 405 have a hollow central lumen for receiving a guide wire.


In yet a further embodiment, the distal end of the clot treatment device shall have a flexible, atraumatic extension from the device. In an alternative embodiment, the tip 405 is tapered to better penetrate the clot material in the vessel.


In preferred embodiments the clot treatment device 402 of the present technology has a generally cylindrical shape that, during use, creates a flow lumen through the clot material that restores significant blood flow across a clot. The treatment device 402 is not, however, limited to a generally cylindrical shape. For example, the shape can be generally conical, generally concave or generally convex along its axis such that the clot treatment device 402 creates a lumen for restoring the blood flow.



FIG. 5A shows one embodiment of the treatment device 402 in a low-profile, undeployed state in which the clot treatment device is configured to fit within a delivery catheter, and FIG. 58 shows the clot treatment device 402 of FIG. 5A in a deployed state configured to restore blood flow and capture clot material for removal. Referring to FIG. 5A, the clot treatment device 402 is compressed to fit within the diameter OL of a lumen 607 of the delivery catheter 606 in the undeployed state. In the deployed state shown in FIG. 58, the clot treatment device 402 has a plurality of capture elements, such as a series of radially extending capture portions 406 which are separated from each other by flow restoration portions 412. The flow restoration portions 412 are configured to expand outwardly from the low-profile undeployed state within the delivery catheter lumen 607 to a first cross-sectional dimension 01 (e.g., diameter) in the deployed state. For example, the flow restoration portions 412 can be generally cylindrical braided sections that expand radially outward from the undeployed stated to the deployed state. In many applications, the first cross-sectional dimension 01 is greater than the diameter OL of the delivery catheter lumen 607. The capture portions 406 are configured to expand outwardly from the low-profile undeployed state to a second cross-sectional dimension 02 greater than the first cross-sectional dimension 01 in the deployed state. As explained in more detail below, the capture portions 406 can project into the clot such that they extend transverse to a longitudinal axis L-L of the clot treatment device 402, while the flow restoration portions 412 expand radially outward into the clot to open a passage through which blood can quickly resume flow through the vessel. The clot treatment device 402 can be porous so blood flows therethrough. In this regard, many embodiments of the clot treatment device 402 are made from a mesh or braided material. The material can be a super-elastic material such as Nitinol or an alternative material such as cobalt chrome alloy. The device can be made from a wire lattice, wire braid or stent. Specific preferred embodiments are discussed throughout this specification.


Referring again to FIG. 58, the clot treatment device 402 can comprise a single mesh structure that is generally cylindrical in the low-profile undeployed state (shown in FIG. 5A). The series of radially extending capture portions 406 accordingly extend from the same mesh as the corresponding series of flow restoration portions 412. The flow restoration portions 412 can be generally cylindrical sections in the deployed state, or in other embodiments the flow restoration portions 412 may taper in the distal direction individually and/or collectively to form a conical lumen (not shown). Each of the capture portions 406 can be a radial or otherwise transversely projecting disk that projects outward relative to the flow restoration portions 412.


The clot treatment device 402 can self-expand from the undeployed state to the deployed state. For example, the clot treatment device 402 can be a shape-memory material, such as Nitinol, and may be formed as a braid or a stent that is set to have the expanded configuration of the deployed state shown in FIG. 58 unless it is otherwise deformed or constrained, such as being elongated along the longitudinal axis L-L to fit within the delivery catheter 606 as shown in FIG. 5A. In other embodiments, the clot treatment device 402 can be actuated by a push/pull wire, tube or coil to move from the low-profile undeployed state to the expanded deployed state as explained in more detail below with reference to FIGS. 10-12.



FIGS. 1-6F show embodiments of methods for restoring blood flow and retrieving/removing clot material with the clot treatment device 402 in a body lumen L.


Referring to FIGS. 1A, 1B and 6A, a guide wire 602 is inserted into the patient via an introducer 102 and maneuvered through the femoral vein FV into the inferior vena cava IVC to the heart. As stated above, access can also be achieved through one of the veins leading to the superior vena cava SVC. The guide wire 602 is then urged through the right atrium RA, through the tricuspid valve TV, through the right ventricle RV, through the pulmonary valve PV to the main pulmonary artery MPA and then to a location of the clot 100 in one of the branches or lumens L of either the right or left pulmonary artery RPA, LPA. In several embodiments, the guide wire 602 is extended through the clot 100 in the body lumen Las shown in FIG. 6A.


Referring to FIG. 68, a guide catheter 604 is placed over the guide wire 602 and moved to a location where a distal end of the guide catheter 604 is positioned proximal to the clot 100. At this point, the guide wire can optionally be withdrawn. However, in the embodiment shown in FIG. 6C, the guide wire 602 remains positioned through the clot 100 and a delivery catheter 606 is then moved through the. guide catheter 604 over the guide wire 602 and pushed through the clot 100.


Referring to FIG. 60, the guide wire 602 is then withdrawn and the clot treatment device 402 in its undeployed (i.e., compressed) state is then moved through the delivery catheter 606 until it is positioned at the distal end of the delivery catheter 606. Alternatively, if an over-the-wire device configuration (as shown in FIG. 10) is used, the guide wire 602 may be left in place while the treatment device 402 is deployed and retracted. Referring to FIG. 6E, the delivery catheter 606 is then retracted in a proximal direction while maintaining forward pressure on the clot retrieval device 402 via the pusher wire 401 so that the clot treatment device 402 is exposed and released from the delivery catheter 606. The clot treatment device 402 radially expands into the clot 100 and, in some embodiments, at least a portion of the clot treatment device 402 expands distal of the clot 100. For example, at least one of the radially extending capture portions 406 of the clot treatment device 402 is located distal to the clot 100 upon expansion of the clot treatment device 402. Additionally, the flow restoration portions 412 between the capture portions 406 also expand outwardly against a portion of the clot 100 to form a flow passage 430 though the clot treatment device 402.


The clot treatment device 402 accordingly restores blood flow through the clot 100 immediately or at least quickly after expanding to the deployed state as shown by arrows 407 in FIG. 6E. More specifically, the blood freely moves through the mesh of the clot treatment device 402, travels through the device lumen and exits the clot treatment device 402 distal to the clot 100. As a result, the acute condition of blockage is mediated thus immediately improving the circulation of oxygenated blood in the patient.


The restoration of blood flow is anticipated to equate with restoration of a substantial portion of the normal blood flow rate for the patient. In less severe. e.g., “sub-massive,” pulmonary embolism patients, the clot treatment device 402 may increase blood flow rate by at least about 50 ml|min, at least about 150 ml|min or between about 100 to 250 ml|min. In severe, e.g., “massive,” pulmonary embolism patients, a larger amount of the pulmonary artery flow is compromised. Hence, in some embodiments, at least about 500 ml/min of blood flow rate may be restored. Moreover, at least a portion of the flow restoration is expected to occur prior to the removal of the clot 100, or any portion thereof.


The restoration of blood flow by the clot treatment device 402 can be achieved in a low pressure environment. For example, the pressure in the target vessel can be less than 60 mmHg and the blood can be venous blood, substantially non-oxygenated blood or low oxygenated blood.


In addition to restoring blood flow, the expansion of the clot treatment device 402 also deforms the clot material by pushing, penetrating and/or otherwise cutting into the clot material. This enhances the subsequent removal of the clot 100 since portions of the clot 100 may be captured and retained (1) between the radially extending portions 406; (2) through the pores of the mesh forming the radially extending portions 406; (3) along the longitudinal cylindrical sections 412 between the radially extending portions 406 of the removal device 402; and (4) within the clot treatment device 402 itself.


As can be understood from the above description and figures, the deployment of the clot treatment device 402 results in an outwardly expanding generally cylindrical force being urged against an inner surface of the clot 100 because the flow restoration portions 412 expand to the first cross-sectional dimension D1 greater than the diameter DL of the delivery catheter lumen 607. This force pushes the clot material outwardly and creates a lumen through which blood flow is restored. As can also be appreciated, the presence of the radially extending capture portions 406 on the clot treatment device 402 causes the outwardly expanding generally cylindrical force to vary in magnitude along the axis of the clot treatment device 402. The force on the clot material may be greater at the locations of the radially extending capture portions 406.


In braided embodiments of the clot treatment device 402, deployment/expansion of the device leads the filaments of the braid to change their angular orientation with respect to the axis of the device. This angular change may improve or enhance adherence of clot material to the clot treatment device 402.


After the clot treatment device 402 has been expanded and blood flow restored, the user then retracts the clot treatment device 402 in a proximal direction as shown in FIG. 6F. Sinethe capture portions 406 extend transverse to the longitudinal dimension of the vessel, the capture portions 406 form transverse surfaces relative to the force exerted against the clot 100 as the clot treatment device 402 is pulled in the proximal direction. The capture portions 406 accordingly enhance the ability of the clot treatment device 402 to securely dislodge and retain the clot 100 as the clot treatment device 402 is moved axially along the vessel to retrieve the clot 100 from the patient. In one embodiment, the clot treatment device 402 and the delivery catheter 606 are pulled back simultaneously into the guide catheter 604. This is followed by the entire apparatus (e.g., clot treatment device 402, delivery catheter 606 and guide catheter 604) being withdrawn through the heart and the venous circulation and out from the body.


As further shown in FIG. 6F, the clot treatment device 402 may elongate as it is being withdrawn into the guide catheter 604 due to the resistance it encounters from the presence of clot material of the clot 100. The presence of the radially extending portions 406 may allow elongation that enhances the capability of the device 402 to capture the maximum amount of clot material. This is further discussed below with respect to the surface area and expansion ratio of preferred embodiments of the clot treatment device 402.


It will be appreciated that variations in the above-described method are contemplated. For example, in certain circumstances a guide catheter 604 may not be necessary or desirable and the user may choose to use only the delivery catheter 606 for placing and manipulation of the clot treatment device 402. As a further example, the clot may be of such a nature that the user may desire repeat the above-described process, or at least portions of it, in order to more fully remove the clot 100 or clot material.


Referring next to FIGS. 7A-78, it may be advantageous to include the use of a collection or funnel catheter 612 to assist in the removal of the clot 100. Such a funnel catheter 612 has an expandable portion 614 at its distal end and may be situated between the guide catheter 604 and the delivery catheter 608 or may be part of the guide catheter 604. In the presence of the collection catheter 612, the clot treatment device 402 is pulled proximally into the collection catheter 612 such that the clot or portions of it are captured within the collection catheter 612. In an alternative embodiment, the collection catheter 612 can be pushed distally over the clot treatment device 402 such that the collection catheter 612 captures the clot or portions thereof. If the collection catheter 612 is separate from the guide catheter 606, the collection catheter with the clot treatment device 402 is then pulled into the guide catheter for ultimate removal of all devices (and the clot) from the patient.


In certain circumstances, it may be advisable to remove the clot 100 without capturing it in the guide catheter 606 or the collection catheter 612 (if used) and remove the clot 100 by withdrawing the entire system, e.g., guide catheter 605, delivery catheter 604, clot treatment device 402 and collection catheter 612 (if used) simultaneously.


In several embodiments, the expandable portion 614 of the collection catheter 612 is a conical funnel or other tapered member constructed from a mesh, braid or stent structure. Such structure assists in retrieving and containing the clot material in the withdrawal process. In yet further preferred embodiments, the collection catheter 612 contains structural features to assist in the expansion of the expandable portion 614 and to hold the expandable portion 614 open towards the wall of the blood vessel. Such features (not shown) include interwoven support struts, self expanding material (e.g., Nitinol), longitudinal wire supports, stent supports, polymeric webbing, etc.


In another embodiment of the present invention, a vacuum apparatus may be used to aid in the removal of the clot material. Referring to FIG. 8, a syringe 802 is shown connected to a vacuum manifold 806 that is in fluid communication with the proximal end of the guide catheter 604. At the time the clot treatment device 402 (and clot material) is being withdrawn into the guide catheter 604 (or the collection catheter 612), vacuum is applied by pulling on the syringe. Alternative sources of vacuum 804 are also acceptable, e.g., a vacuum pump. A system is also contemplated whereby vacuum is actuated automatically when the clot treatment device 402 (and the clot material) is being withdrawn. A representation of the effect of the use of vacuum can be seen with reference to FIG. 78 which shows how vacuum causes flow 701 into the catheter 612.


Referring now to FIGS. 9A-9H, alternative preferred embodiments of the clot treatment device 402 are disclosed.


Referring to FIG. 9A, the radially extending portions 406 between the generally cylindrical sections 412 of the clot treatment device 402 are defined by a cylindrical disk shape with a rounded triangular cross-section.


Referring to FIG. 98, the radially extending portions 406 between the generally cylindrical sections 412 of the clot treatment device 402 are defined by a cylindrical disk shape with a rounded triangular cross-section wherein the diameter of the disk increases along the length of the device 402 thus forming a conical exterior extent.


Referring to FIG. 9C, the radially extending portions 406 between the generally cylindrical sections 412 of the clot treatment device 402 are defined by a cylindrical disk shape with a rectangular cross-section.


Referring to FIG. 90, the radially extending portions 406 between the generally cylindrical sections 412 of the clot treatment device 402 are defined by a cylindrical disk shape with a linear (non-rounded) triangular cross-section.


Referring to FIG. 9E, some of the radially extending portions 406 between the generally cylindrical sections 412 of the clot treatment device 402 are defined by a cylindrical disk shape with a rounded cross-section and others have a rectangular cross section.


Referring to FIG. 9F, the radially extending portions 406 between the generally cylindrical sections 412 of the clot treatment device 402 alternate between cylindrical disk shape with a T-shaped cross-section and a flare-shaped cross-section.


Referring to FIG. 9G, the radially extending portions 406 between the generally cylindrical sections 412 of the clot treatment device 402 are defined by a partial cylindrical disk shapes.


Referring to FIG. 9H, the radially extending portions 406 between the generally cylindrical sections 412 of the clot treatment device 402 are defined by tabs and bumps or protuberances arising from the cylindrical surface of the device 402.



FIG. 10 is a cross-sectional view of another embodiment of the clot treatment device 402 in accordance with the technology having an expandable member 1010, an elongated inner member 1020, and an elongated outer member 1022. The expandable member 1010 is configured to have an undeployed state in which the expandable member 1010 is elongated axially to have a low profile that fits within a delivery catheter as shown in FIG. 4. The expandable member 1010 is further configurable into a deployed state in which the expandable member 1010 forms a flow channel 1012 for restoring blood flow through the region obstructed by the clot. The expandable member 1010, for example, can be a mesh, braid, stent-type device, or other suitable member through which blood flows in the deployed state. In one embodiment, the expandable member 1010 is a continuous braid formed from a shape-memory material that has been heat set such that, in the deployed state, the expandable member 1010 has a plurality of flow restoration portions 412 that expand to the first cross-sectional dimension 01 to form the flow channel 1012 and a plurality of capture portions 406 that expand to the second cross-section dimension 02 greater than the first cross-sectional dimension 01. The flow restoration members 412 accordingly exert an outward force (arrows 0) against clot material (not shown) to create the flow channel 1012, and the capture portions 406 accordingly exert a longitudinal force L (arrows L) against the clot material as the clot treatment device 402 is moved proximally.


The elongated inner member 1020 can be a tube or coil having inner lumen configured to receive the guidewire 602 for over-the-wire or rapid exchange delivery of the expandable member 1010 to the clot. The outer elongated member 1022 can be a tube or coil having a lumen configured to receive the inner elongated member 1020 such that the inner elongated member 1020 and/or the outer elongated member 1022 can move relative to each other along the longitudinal dimension of the clot treatment device 402.



FIGS. 11 and 12 are detailed views of a distal portion 1011a (FIG. 11) and a proximal portion 1011b (FIG. 12) of the expandable member 1010 of the clot treatment device 402 shown in FIG. 10. Referring to FIG. 11, the distal portion 1011a is attached to a distal end of the inner elongated member 1020 by the tip 405. The tip 405 can be blunt as described above with reference to the embodiment of the clot treatment device 402 shown in FIG. 4, or the tip 405 can have a tapered distal portion 1040 configured to pass through the clot as shown in FIG. 11. Additionally, the tip 405 can have a proximal opening 1042 configured to receive the distal end of the inner elongated member 1020 and the distal end of the expandable member 1010. Referring to FIG. 12, the proximal portion 1011b is attached to the distal end of the outer elongated member 1022 by a proximal hub 1030. For example, the distal and proximal portions 1011a and 1011b can be attached to the inner elongated member 1020 and the outer elongated member 1022, respectively, using welds, adhesives, crimping or clamping forces, and/or other suitable attachment mechanisms.


In the operation of the clot treatment device 402 shown in FIGS. 10-12, the expandable member 1010 can self-expand from the undeployed state to the deployed state without an actuator. For example, as a delivery catheter is drawn proximally to release the expandable member 1010, the inner elongated member 1020 can be held in place to hold the distal portion 1011a of the expandable member 1010 distally of the clot. As the distal end of the delivery catheter moves proximally, the outer elongated member 1022 will slide distally as the expandable member 1010 expands until the expandable member 1010 reaches its predetermined deployed size or otherwise reaches equilibrium with the clot. In other embodiments, the inner elongated member 1020 and/or the outer elongated member 1022 can be actuators that are moved proximally and/or distally to control the radial expansion and/or the radial contraction of the expandable member 1010.



FIGS. 13 and 14 are detailed views of the proximal and distal portions 1011b and 1011a, respectively, of an expandable member 1010 and other components of a clot treatment device 402 in accordance with another embodiment of the technology. In this embodiment, the clot treatment device 402 has a proximal tube 1410 (FIG. 13) and an expansion element 1420 having one end attached to the proximal tube 1410 and another end attached to the distal portion 1011a (FIG. 14) of the expandable member 1010. The expansion element 1420, for example, can be a coil or spring that is stretched from its normal state when the expandable member 1010 is the low-profile, undeployed state inside the delivery catheter. As the distal portion 1011a and then the proximal portion 1011b of the expandable member 1010 are released from the delivery catheter, the expansion element 1420 contracts axially under its own stored spring force causing the expandable member 1010 to contract axially and expand radially outward. In the embodiments where the expandable member 1010 is self-expanding, the expansion element 1420 assists the expansion of the expandable member 1010. In other embodiments, the expandable member 1010 may not be self-expanding or may be inherently spring-biased into the low-profile undeployed state, and the expansion element 1420 can have enough stored energy when it is stretched in the low-profile undeployed state to pull the distal portion 1011a and the proximal portion 1011b of the expandable member 1010 toward each other and thereby radially expand the expandable member 1010.


In the foregoing embodiments, the radially extending capture portions 406 provide more surface area along the device than a device that is uniformly cylindrical. Moreover, the radially extending capture portions 406 extend transversely to the longitudinal dimension of the device to more effectively transfer the axial force as the device is moved axially along the vessel after deployment. Such increased surface area facilitates the treatment and/or retrieval of a much larger portion of the clot 100 than is generally feasible with a uniformly cylindrical device. For example, in a preferred embodiment of the clot treatment device 402, the device will have an external surface area between 1.5× and 6× the surface area of a uniformly cylindrical device of the same general diameter of the cylindrical sections 412. In other preferred embodiments the ratio will be 2× to 4×.


This is advantageous particularly during retraction of the clot treatment device 402 through the clot 100. As shown in FIG. 6F, the clot treatment device 402 may become elongated as it is being withdrawn through the clot 100. Such elongation causes the clot material to encounter greater surface area of the clot treatment device 402 than would otherwise occur with a device that was only generally cylindrical, i.e., that did not incorporate radially extending portions 406. Accordingly the clot treatment device 402 is particularly adept at capturing the maximum amount of clot material during withdrawal.


The clot treatment device 402 is intended for use in large vessels, i.e., vessels with a diameter greater than 8 mm. For example, the diameter of the pulmonary arteries typically range from 15 to 30 mm whereas the first branches of the pulmonary arteries typically range from 10 to 15 mm and the secondary and tertiary branches typically range from 5 to 10 mm. At the same time, however, it is important to minimize the size of catheter providing access to the clot 100. Accordingly, the clot treatment device 402 has a large expansion ratio. In a preferred embodiment the expansion ratio from the diameter of the cylindrical sections 412 in the collapsed state to the expanded state will be between 4 and 8. In another preferred embodiment the ratio will be between 5 and 7. The large expansion ratio also enables the formation of a flow channel in the clot 100 that is large, e.g., on the order of 4-8 mm.


The radially extending portions 406, in their fully expanded position are intended to have a size that matches the diameter of the target blood vessel. However, the diameters may be slightly larger than the vessel diameter so to apply greater radial force against the blood vessel (without causing trauma) in those circumstances when it is desirable to improve clot collection. Similarly, in those circumstances where there is a concern of creating trauma on delicate blood vessels, the radially extending portions 406 may have a diameter that is smaller than the vessel diameter. It is contemplated that different sizes of the device 402 will be available for selection by the user for a particular presentation of the patient.


As for the length of the clot treatment device 402, it is known that a typical pulmonary embolism will have a length within the range between about 2 em and 10 em and sometimes between about 1 em and 20 em. Accordingly, in a preferred embodiment, the clot treatment device 402 will have a length that exceeds the length of the embolism so that a portion of the clot treatment device is positioned distal of the clot 100 during expansion.


With regard to the delivery catheter 606, in a preferred embodiment for use with a pulmonary embolism, the size will be around 1 F-6 F. Smaller diameters will pass through the clot 100 more easily. In addition, the delivery catheter 606 may have stiffness characteristics to assist in making sure the delivery catheter 606 passes through the clot in a smooth manner. Such stiffness characteristics include self expanding Nitinol wire braids or stent structures that are contained within the structure of the delivery catheter 606. The delivery catheter 606 also has sufficient flexibility so that it may carry the clot treatment device 402 and still pass through a tortuous vessel path as described above starting with insertion of the delivery catheter 606 in the femoral vein FV.


In some preferred embodiments, the method and device in accordance with the present invention may reduce the Mean Resting Pulmonary Artery Pressure (MRPAP). Upon at least partial relief from the clot 100, MRPAP may be reduced by about 20-50 mmHg to a normal range of 8-20 mmHg. In some embodiments, the reduction in MRPAP may be about 25-50%. In some embodiments, the reduction in MRPAP may be about 15% to 40% and in other embodiments between about 30% and 75%.


Such a reduction in MRPAP can occur in two steps. A first step is when the clot treatment device 402 is first deployed and blood flow is at least partially restored. A second step may be when the clot treatment device 402 is retracted and at least some of the clot 100 is removed from the vessel. A third step may be after the clot treatment device 402 has been removed and the effect of the body's own processes and/or thrombolytic drugs that may have been used before, during or after the procedure take effect upon clot that has been disrupted by the clot treatment device.



FIG. 15 is a side view of an embodiment of a guide catheter 1500 for use with any of the foregoing embodiments of the clot treatment devices 402 (not shown in FIG. 15). The guide catheter 1500 can include a shaft 1502 having a sufficiently large lumen to accommodate the delivery catheter 606 (FIGS. 4 and 5A). The guide catheter 1500 can further include an expandable guide member 1510 at the distal end of the shaft 1502 configured to expand radially outward to contact or nearly contact the vessel wall VW. The guide member can be formed from a permeable, radially expanding material, such as a mesh or other macroporous structure (e.g., a braid of wires or filaments). The guide member 1510, for example, may be formed from a tubular braid of elastic or super-elastic filaments such as Nitinol that has been heat set into the desired expanded shape. The permeable, radially expanding guide member 1510 may have advantages over an occlusive member such as a balloon or impermeable funnel. For example, the guide member 1510 allows a substantial amount of blood flow BF to continue flowing through the blood vessel where therapy is being directed. In addition, the guide member 1510 positions the shaft 1502 and delivery catheter 606 at or near the center of the vessel. The clot treatment device 402 (not shown in FIG. 15) may also be substantially self-centering upon deployment, and the guide member 1510 may further guide the clot material captured by the clot treatment device 402 into the shaft 1502 as the clot treatment device 402 moves into proximity of the distal end of the shaft 1502. This is expected to enhance aspiration of the clot material. For example, in the embodiment shown in FIG. 15, the radially expanding guide member 1510 has a funnel shape adjacent the distal end of the shaft 1502 to guide thrombus material into the distal opening of the shaft 1502 where it can be more readily aspirated.


The radially expanding guide member 1510 may also be formed by conventional machining, laser cutting, electrical discharge machining (EDM) or other means known in the art to make a fenestrated, mesh or porous structure that can be affixed near the distal end of the shaft 1502. In some embodiments the radially expanding guide member 1510 may self-expand, but in other embodiments it may be actuated by an operator using, for example, electrical or electromechanical means. By having a porous radially expanding guide member 1510, the guide catheter 1500 may be substantially centered within a vessel without blocking a large portion of the flow around the catheter. In some embodiments, the radially expanding guide member 1510 may block less than about 50% of the flow about the catheter and in other embodiments less than about 25% of the flow. When the guide member 1510 is made with a braid of filaments (e.g. wires), it may be formed from a tubular braid. In some embodiments, the tubular braid may be formed with approximately 12 to approximately 144 filaments, or in other embodiments from about 36 to about 96 filaments. The pores as measured by the largest circle that can be inscribed within an opening of the mesh may be between about 0.5 mm and 5 mm.



FIGS. 16 and 17 show additional embodiments of guide members 1610 and 1710, respectively, that can be used instead of or in addition to the guide member 1510. Referring to FIGS. 15 and 16, one or both ends of the tubular braid of the guide members 1510 and 1610 may be inverted and attached to the catheter body. Referring to FIG. 17, neither end of the guide member 1710 is inverted. With the distal end inverted, it advantageously may form a funnel adjacent the distal opening of the catheter that may enhance clot capture and aspiration.



FIG. 18 shows an embodiment of a guide catheter 1900 having a shaft 1902 and a guide member 1910 in accordance with another embodiment of the technology. In the embodiment shown in FIG. 18, the guide member 1910 has a tapered or funnel shape, and includes a non-permeable portion 1912 and a permeable portion 1914. The permeable portion 1914 can comprise a flared radially expanding mesh that has, at least in part, a tapered or funnel shape, and the non-permeable portion 1912 may have a substantially non-porous or otherwise non-permeable material or coating over the mesh. Preferably, the non-permeable material is a highly elastic material such as polyurethane, silicone, latex rubber and the like so that it can flex with the expansion of the mesh. In some embodiments, the non-permeable material covers a proximal portion of the mesh as shown in FIG. 18. The non-permeable portion 1912 may divert some flow away from the distal end of the catheter. The covering may cover a portion of the mesh to a diameter “d”. In some embodiments, the diameter d of the covering is less than about 75% of the diameter “D” of the mesh funnel. In some embodiments, the diameter d may be less than about 50% of diameter D. The concept of a non-permeable material can also be applied to the guide catheter 1500 shown above in FIG. 15. For example, the expandable member 1510 of the guide catheter 1500 can have a non-permeable portion 1512 at the proximal portion of the expandable guide member 1510 similar to the non-permeable portion 1912 shown and described with reference to FIG. 18.



FIGS. 19-27 show additional embodiments of clot treatment devices 402 in accordance with the present technology. The embodiments of the clot treatment devices 402 shown in FIGS. 19-27 can restore blood flow and capture clot material in a manner similar to the embodiments of the clot treatment devices 402 described above with respect to FIGS. 4-18. The embodiments of the clot treatment devices 402 related to FIGS. 19-27 can also be made from the same materials and be deployed in the same manner as described above with respect to FIGS. 4-18. As such, many of the features, materials and benefits of the clot treatment devices 402 shown in FIGS. 4-18 are applicable to the clot treatment devices shown in FIGS. 19-27.



FIG. 19 shows an embodiment of the clot treatment device 402 that includes a plurality of capture elements, such as clot engagement (“CE”) members 1952. The CE members 1952 can be (a) arcuate as shown in FIG. 19, (b) bent at one or more angles (e.g., 30°, 45°, 60°, 90°, 135°, etc.), and/or (c) straight (e.g., project outward along a straight line). In some embodiments, the clot treatment device 402 can include a combination of arcuate, angled and/or straight CE members. In other embodiments, the clot treatment device 402 can include a single CE member 1952. The CE members 1952 can be interwoven into the mesh structure of the device 402 (see FIG. 21). The CE members 1952 can also be bonded, soldered, welded, tied or otherwise secured to the mesh structure or mechanically interlocked with the mesh structure. As the clot treatment device 402 is unsheathed during deployment, the CE members 1952 can radially extend and form a heat-set shape configured to penetrate and fasten the clot to the treatment device 402. The CE members 1952 can accordingly define hook-like capture elements in several embodiments of the present technology.


The CE members 1952 can be disposed about an exterior surface of the device 402. For example, as shown in FIG. 19, the CE members 1952 can be arranged in one or more circumferential rows 1954 that are evenly positioned along a longitudinal axis of the device 402. In other embodiments, the CE members 1952 can have any suitable arrangement and/or positioning about the device (e.g., arranged in a helical pattern, off-set rows, random, or irregular or otherwise uneven/non-uniform spacing, etc.).


As shown in FIG. 19, the CE members 1952 can curve proximally such that a concave portion 1956 of the CE members 1952 face a proximal region 402b of the device 402. In some embodiments, the CE members 1952 can curve distally such that a concave portion of the CE members 1952 face a distal region 402a of the device 402 (not shown). In particular embodiments, the clot treatment device 402 includes both distally-curving and proximally-curving CE members.


The CE members can have a single radius of curvature or have regions with different radii or have a complex or changing radius of curvature. For example, as shown in FIG. 20, one or more of the CE members 1952 can have a first portion 1958 that has a first radius R and a second portion 1960 (e.g., the distal region of the CE member 1952) that has a second radius r that is smaller than the first radius R. In some embodiments, the first radius R may range from about 2 mm to about 15 mm, and the second radius r may range from about 0.25 mm to about 5 mm. Additionally, the CE members 1952 can have a range of arc lengths. For example, in some embodiments the CE members 1952 can have an arc length greater than 180 degrees. In certain embodiments, the arc length can be between 180 degrees and 330 degrees.



FIG. 22 shows another embodiment of a CE member 2202 having a V-shaped base 2204 that branches into a first arm 2206a and a second arm 2206b. The V-shaped base 2204 and/or any portion of the first and/or second arms 2206a, 2206b can be interwoven into the mesh structure of the clot treatment device 402, as shown in FIGS. 24 and 25. In some embodiments, the angle a between the first and second arms 2206a, 2206b may be between about 40 degrees and about 100 degrees. Although FIG. 24 shows a plurality of such CE members 2202 disposed about a clot treatment device 402, in other embodiments the device 402 can only include a single CE member 2202.


As shown in FIG. 25, the first arm 2206a and the second arm 2206b can extend into a first distal portion 2208a and a second distal portion 2208b, respectively, where the first distal portion 2208a and the second distal portion 2208b are generally arcuate. As shown in FIG. 24, in some embodiments the first distal portion 2208a and the second distal portion 2208b can be generally linear.


Referring to FIG. 26, two or more CE members can be connected to form a circumferential structure 2602 that extends around at least a portion of a circumference of a clot treatment device 402. The device 402 can include one or more circumferential structures 2602 spaced along a longitudinal axis of the device. These circumferential structures 2602 can allow for the CE members to flex with the mesh structure as it expands and contracts. In some embodiments, the angle 8 formed by the circumferential structure 2602 can be between about 40 degrees and about 100 degrees.



FIG. 23 shows one embodiment of an CE member 2302 having a double-wire arcuate portion 2306. Referring to FIG. 27, in some embodiments, the clot treatment device 402 can include a plurality of CE member 1952 and a radially extended member 406 at a distal end. The radially extended member 406 could be a disc, balloon, screen or other clot capture member.


EXAMPLES

Several examples of the present technology are as follows:


1. A device for treating a pulmonary embolism, comprising:

    • an expandable flow restoration portion; and
    • a plurality of capture elements including at least a first capture element and a second capture element, wherein the flow restoration portion is between the first and second capture elements, and wherein the flow restoration portion and the capture elements are configured to move from a low-profile undeployed state sized to fit within a delivery catheter to a deployed state in which the flow restoration portion has a first cross-sectional dimension greater than that of the low-profile state such that the flow restoration portion forms a flow channel through the device and the capture elements project outwardly from the flow restoration portion.


2. The device of example 1 wherein the flow restoration portion and the capture elements comprise an expandable braided material that is heat set to have the deployed state.


3. The device of any of examples 1 and 2 wherein the flow restoration portion and the capture elements are integrally formed from a common braided material.


4. The device of any of examples 1-3, further comprising a plurality of flow restoration portions and the capture elements comprise a series of radially extending capture portions, and wherein the radially extending capture portions are separated from each other by individual flow restoration portions.


5. The device of example 4 wherein the flow restoration portions comprise expandable cylindrical sections and the capture elements comprise radially expandable disk-like capture portions of the braided material.


6. The device of example 1 wherein the flow restoration portion comprises a radially expandable cylindrical braided material and the capture elements comprise protuberances projecting from the flow restoration portion.


7. The device of any of examples 1-6 wherein the flow restoration portion has an expansion ratio from the undeployed state to the deployed state of approximately 1:4 to 1.8.


8. The device of any of examples 1-6 wherein the flow restoration portion has an expansion ratio from the undeployed state to the deployed state of approximately 1:5 to 1.7.


9. The device of any of examples 1-8 wherein the flow restoration portion has a diameter of approximately 4-8 mm in the deployed state to restore blood flow through a pulmonary embolism.


10. The device of any of examples 1-9 wherein the flow restoration portions and the capture elements comprises a self-expanding braided material, and the capture elements comprise capture portions that have a second diameter greater than the first cross-sectional dimension of the flow restoration portions in the deployed state.


11. The device of any of examples 1-3 and 6-9 wherein the flow restoration portion comprises a single expandable braided tube, and the capture elements comprise clot engagement members configured to project from the flow restoration portion in the deployed state.


12. The device of example 11 wherein the clot engagement members comprise arcuate members that form hook-like elements projecting from the flow restoration portion.


13. The device of example 11 wherein the clot engagement members are formed from wires of the expandable braided tube that defines the flow restoration portion.


14. The device of example 11 wherein the clot engagement members are formed from separate wires that project through interstices of the expandable braided tube that defines the flow restoration portion.


15. A pulmonary embolism treatment device, comprising:

    • an outer elongated member having a distal end;
    • an inner elongated member within the outer elongated member, wherein the inner elongated member and/or the outer elongated member slides relative to the other, and wherein the inner elongated member has a distal end; and
    • an expandable member having a proximal portion attached to the distal end of the outer elongated member and a distal portion attached to the distal end of the inner elongated member, the expandable member having a flow restoration portion and a plurality of capture elements arranged along the flow restoration portion, wherein the flow restoration portion and the capture elements are configured to move from a low-profile undeployed state sized to fit within a delivery catheter to a deployed state in which the flow restoration portion has a first cross-sectional dimension greater than that of the low-profile state that defines a flow channel through the device and the capture elements project outwardly from the flow restoration portion.


16. The pulmonary embolism treatment device of example 15 wherein the expandable member comprises a braided material.


17. The pulmonary embolism treatment device of example 15 wherein the device has a plurality of flow restoration portions and the capture elements are separated by individual flow restoration portions, and wherein (a) the capture elements comprise capture portions formed from a continuous shape-memory braided material heat-set to the deployed state and (b) the capture portions project from the flow restoration portions to a second cross-sectional dimension in the deployed state.


18. The pulmonary embolism treatment device of example 17 wherein the flow restoration portions comprise cylindrical portions and the first cross-sectional dimension comprises a first diameter in the deployed state, and the capture portions comprise disk-like projections having a second diameter greater than the first diameter in the deployed state.


19. The pulmonary embolism treatment device of any of examples 11-18 wherein the flow restoration portion(s) have an expansion ratio from the undeployed state to the deployed state from 1:4 to 1:8.


20. The pulmonary embolism treatment device of any of examples 11-18 wherein the flow restoration portion(s) have an expansion ratio from the undeployed state to the deployed state from 1:5 to 1:7.


21. The pulmonary embolism treatment device of any of examples 11-20 wherein the first elongated member comprises an outer tube and the second elongated member comprises an inner tube within the outer tube.


22. The pulmonary embolism treatment device of any of examples 11-20 wherein the first elongated member comprises an outer tube and the second elongated member comprises a coil within the outer tube.


23. The pulmonary embolism device of any of examples 11-20 wherein the first elongated member comprises an outer coil and the second elongated member comprises an inner coil.


24. The pulmonary embolism treatment device of any of examples 11-23 wherein the flow restoration portion(s) and the capture elements comprise a self-expanding braided material.


25. The pulmonary embolism treatment device of any of examples 11-24 wherein the outer elongated member is configured to slide distally with respect to the inner elongated member to move the expansion member from the undeployed state to the deployed state.


26. The pulmonary embolism treatment device of any of examples 11-25, further comprising a guide catheter having a shaft with a distal end and an expandable guide member at the distal end of the shaft, wherein the shaft has a lumen configured to receive the expandable member in the undeployed state.


27. The pulmonary embolism treatment device of example 26 wherein the expandable guide member comprises radially expandable mesh.


28. The pulmonary embolism treatment device of example 27 wherein the radially expandable mesh comprises a braided material.


29. The pulmonary embolism treatment device of any of examples 26-28 wherein the expandable guide member has a funnel shape.


30. The pulmonary embolism treatment device of any of examples 26-29 wherein at least a portion of the expandable guide member is permeable to allow blood to flow through the expandable guide member when the expandable guide member is expanded.


31. The pulmonary embolism treatment device of any of examples 26-29 wherein the expandable guide member has a non-permeable portion at the distal end of the shaft and a permeable portion extending distally from the non-permeable portion.


32. A pulmonary embolism treatment device, comprising:

    • an elongated member having a distal end;
    • an expansion portion having a proximal end attached to the distal end of the elongated member, and the expansion portion having a distal end; and
    • an expandable member having a proximal portion attached to the distal end of the elongated member and a distal portion attached to the distal end of the expansion portion, the expandable member having at least one of flow restoration portion and a plurality of capture elements arranged such that the capture elements are separated by individual flow restoration portion, wherein the flow restoration portion and the capture elements are configured to move from a low-profile undeployed state sized to fit within a delivery catheter to a deployed state in which (a) the flow restoration portion has a first cross-sectional dimension greater than that of the low-profile state that defines a flow channel through the device and (b) the capture elements project outwardly from the flow restoration portion, and wherein the expansion portion is stretched from a normal state when the expandable member is in the undeployed state such that the expansion portion is configured to axially contract the expandable member from the undeployed state to the deployed state.


33. A method of treating a pulmonary embolism, comprising:

    • delivering an embolectomy device through the heart to a pulmonary embolism that at least partially restricts blood flow through a pulmonary vessel, wherein the embolectomy device has a plurality of capture elements separated by an expandable cylindrical section;
    • deploying the embolectomy device within the pulmonary embolism by expanding the cylindrical section into the pulmonary embolism so that the cylindrical section forms an expanded flow channel through the pulmonary embolism and thereby restores blood flow through the pulmonary embolism and by expanding the capture elements to a greater extent than the cylindrical section so that at least a portion of the pulmonary embolism is captured the capture elements;
    • moving the embolectomy device and at least a portion of the pulmonary embolism along the pulmonary vessel; and
    • withdrawing the embolectomy device and at least a portion of the pulmonary embolism from the pulmonary vessel.


34. The method of example 33 wherein deploying the embolectomy device comprises expanding a plurality of radial extendable capture elements of the embolectomy device.


35. The method of example 34, wherein at least one of the plurality of radial extendable capture elements is expanded distal relative to the pulmonary embolism.


36. The method of example 33, further comprising applying vacuum while withdrawing the embolectomy device.


37. The method of example 36, wherein withdrawing the embolectomy device includes urging the portion of the pulmonary embolism into a funnel catheter.


38. The method of example 37, wherein deploying the embolectomy device comprises expanding the device such that a surface area of the embolectomy device expands within a range of at least 200% to 400% of the surface area of a uniformly cylindrical device.


39. The method of example 33 wherein deploying the embolectomy device comprises expanding the generally cylindrical section by 400% to 800% of its diameter in the undeployed state.


40. The method according to and of examples 33-39 wherein deploying the embolectomy device comprises expanding a braided material into a preset shape having a plurality of radially extending disk-like capture portions that define the capture elements.


Although the invention has been described in terms of particular embodiments and applications, one of ordinary skill in the art, in light of this teaching, can generate additional embodiments and modifications without departing from the spirit of or exceeding the scope of the exampled invention. Accordingly, it is to be understood that the drawings and descriptions herein are proffered by way of example to facilitate comprehension of the invention and should not be construed to limit the scope thereof.

Claims
  • 1. A system for treating a pulmonary embolism, comprising: a clot treatment device including— an expandable flow restoration portion; anda plurality of capture elements including at least a first capture element and a second capture element, wherein the flow restoration portion is positioned between the first and second capture elements, wherein the flow restoration portion and the capture elements are configured to move from a low-profile undeployed state sized to fit within a delivery catheter to a deployed state in which the flow restoration portion has a cross-sectional dimension greater than that of the undeployed state and the capture elements project outwardly from the flow restoration portion, and wherein the flow restoration portion has a first longitudinal dimension and each of the capture elements has a second longitudinal dimension, the first longitudinal dimension being greater than the second longitudinal dimension;a guide catheter having a shaft with a distal end portion, wherein the shaft includes a lumen configured to receive the clot treatment device in the undeployed state; andan expandable guide member at the distal end portion of the shaft, wherein the expandable guide member is configured to guide clot material into the guide catheter as the clot treatment device is withdrawn into the guide catheter.
  • 2. The system of claim 1 wherein at least a portion of the expandable guide member is permeable to allow blood to flow through the expandable guide member.
  • 3. The system of claim 1 wherein the expandable guide member comprises at least one of a self-expanding mesh structure or a self-expanding braided structure.
  • 4. The system of claim 1 wherein the expandable guide member is formed from a tubular braid of elastic or super-elastic filaments that have been heat set to have a desired expanded shape.
  • 5. The system of claim 1 wherein, when the guide catheter is positioned within a pulmonary vessel, the expandable guide member is configured to expand radially outward to contact or nearly contact the pulmonary vessel and block less than about 50% of blood flow about the guide catheter.
  • 6. The system of claim 1 wherein the expandable guide member is configured to position the shaft at or near a center of a pulmonary vessel in which the guide catheter is positioned.
  • 7. The system of claim 1 wherein the expandable guide member has a tapered or funnel shape for guiding thrombus material into a distal opening in the shaft.
  • 8. The system of claim 1 wherein the expandable guide member includes a permeable portion and a substantially non-permeable portion.
  • 9. The system of claim 8 wherein the expandable guide member comprises a mesh, and wherein the non-permeable portion comprises a non-permeable coating formed on a proximal portion of the mesh.
  • 10. The system of claim 1 wherein the expandable guide member has a substantially non-permeable portion affixed to the distal end portion of the shaft and a permeable portion extending distally from the substantially non-permeable portion.
  • 11. The system of claim 10 wherein the permeable portion comprises a radially expanding mesh having a tapered or funnel shape, and wherein the substantially non-permeable portion comprises an elastic material.
  • 12. A system for treating pulmonary embolism, comprising: a clot treatment device including— an outer elongated member having a distal end;an inner elongated member within the outer elongated member, wherein the inner elongated member and the outer elongated member slide relative to each other, and wherein the inner elongated member has a distal end; andan expandable member having a proximal portion fixed to the distal end of the outer elongated member and a distal portion fixed to the distal end of the inner elongated member, the expandable member having a flow restoration portion and a plurality of capture elements arranged along the flow restoration portion, wherein the flow restoration portion and the capture elements are configured to move from a low-profile undeployed state sized to fit within a delivery catheter to a deployed state in which the flow restoration portion has a cross-sectional dimension greater than that of the undeployed state and the capture elements project outwardly from the flow restoration portion, and wherein the flow restoration portion has a first longitudinal dimension and each of the capture elements has a second longitudinal dimension, the first longitudinal dimension being greater than the second longitudinal dimensiona guide catheter having a shaft with a distal end portion, wherein the shaft includes a lumen configured to receive the clot treatment device in the undeployed state; anda radially expandable guide member having a first portion affixed to the distal end portion of the shaft and a second portion extending distally from the first portion, wherein the guide member is configured to guide clot material into the guide catheter as the clot treatment device is withdrawn into the guide catheter.
  • 13. The system of claim 12 wherein, when the guide member is expanded— the guide member defines a distal opening,the first portion has a first diameter, andthe second portion has a second diameter greater than the first diameter.
  • 14. The system of claim 12 wherein, when the guide catheter is positioned within a pulmonary vessel and the guide member is expanded— the first portion of the guide member is substantially non-permeable to divert blood flow away from the distal end portion of the shaft, andthe second portion of the guide member is permeable to allow blood to flow through the guide member and around the guide catheter.
  • 15. The system of claim 12 wherein the first portion is permeable.
  • 16. The system of claim 12 wherein the first portion is substantially non-permeable.
  • 17. The system of claim 12 wherein the second portion comprises a radially expanding mesh having a tapered or funnel shape, and wherein the first portion comprises an elastic material configured to flex with expansion of the second portion.
CROSS-REFERENCE TO RELATED APPLICATION(S)

This application is a continuation of U.S. patent application Ser. No. 15/949,350, filed on Apr. 10, 2018 and entitled Methods and Apparatus for Treating Embolism, which is a continuation of U.S. patent application Ser. No. 14/646,358, filed on May 20, 2015, now issued as U.S. Pat. No. 10,004,531, and entitled Methods and Apparatus for Treating Embolism, which is a 371 U.S. national filing of PCT/US2013/071101, filed on Nov. 20, 2013, and entitled Methods and Apparatus for Treating Embolism, which is a continuation-in-part of U.S. patent application Ser. No. 13/843,742, filed on Mar. 15, 2013, now issued as U.S. Pat. No. 8,784,434 and entitled Methods and Apparatus for Treating Embolism, which claims priority to U.S. Provisional Application Ser. No. 61/750,277 filed Jan. 8, 2013 entitled Devices and Methods for Treatment of Vascular Occlusion and U.S. Provisional Application Ser. No. 61/728,775 filed Nov. 20, 2012 entitled Devices and Methods for Treatment of Vascular Occlusion, all of which are hereby incorporated herein by reference in their entireties.

US Referenced Citations (715)
Number Name Date Kind
2846179 Monckton Aug 1958 A
2955592 Maclean Oct 1960 A
3088363 Sparks May 1963 A
3197173 Taubenheim Jul 1965 A
3435826 Fogarty Apr 1969 A
3515137 Santomieri Jun 1970 A
3675657 Gauthier Jul 1972 A
3892161 Sokol Jul 1975 A
3923065 Nozick et al. Dec 1975 A
4030503 Clark, III Jun 1977 A
4034642 Iannucci et al. Jul 1977 A
4222380 Terayama Sep 1980 A
4243040 Beecher Jan 1981 A
4287808 Leonard et al. Sep 1981 A
4324262 Hall Apr 1982 A
4393872 Reznik et al. Jul 1983 A
4469100 Hardwick Sep 1984 A
4523738 Raftis et al. Jun 1985 A
4551862 Haber Nov 1985 A
4604094 Shook Aug 1986 A
4611594 Grayhack et al. Sep 1986 A
4643184 Mobin-Uddin Feb 1987 A
4646736 Auth et al. Mar 1987 A
4650466 Luther Mar 1987 A
4776337 Palmaz Oct 1988 A
4790812 Hawkins, Jr. et al. Dec 1988 A
4863440 Chin et al. Sep 1989 A
4870953 DonMichael et al. Oct 1989 A
4883458 Shiber Nov 1989 A
4886062 Wiktor Dec 1989 A
4890611 Monfort et al. Jan 1990 A
4898575 Fischell et al. Feb 1990 A
4946440 Hall Aug 1990 A
4960259 Sunnanvader et al. Oct 1990 A
4978341 Niederhauser Dec 1990 A
5059178 Ya Oct 1991 A
5100423 Fearnot Mar 1992 A
5127626 Hilal et al. Jul 1992 A
5129910 Phan et al. Jul 1992 A
5135484 Wright Aug 1992 A
5154724 Andrews Oct 1992 A
5158533 Strauss et al. Oct 1992 A
5158564 Schnepp-Pesch et al. Oct 1992 A
5192274 Bierman Mar 1993 A
5192286 Phan et al. Mar 1993 A
5192290 Hilal Mar 1993 A
5197485 Grooters Mar 1993 A
5329923 Lundquist Jul 1994 A
5360417 Gravener et al. Nov 1994 A
5364345 Lowery et al. Nov 1994 A
5376101 Green et al. Dec 1994 A
5383887 Nadal Jan 1995 A
5389100 Bacich et al. Feb 1995 A
5419774 Willard et al. May 1995 A
5421824 Clement et al. Jun 1995 A
5443443 Shiber Aug 1995 A
5456667 Ham et al. Oct 1995 A
5476450 Ruggio Dec 1995 A
5490859 Mische et al. Feb 1996 A
5496365 Sgro Mar 1996 A
5527326 Hermann et al. Jun 1996 A
5549626 Miller et al. Aug 1996 A
5591137 Stevens Jan 1997 A
5653684 Laptewicz et al. Aug 1997 A
5662703 Yurek et al. Sep 1997 A
5746758 Nordgren et al. May 1998 A
5749858 Cramer May 1998 A
5769816 Barbut et al. Jun 1998 A
5782817 Franzel et al. Jul 1998 A
5800457 Gelbfish Sep 1998 A
5827229 Auth et al. Oct 1998 A
5846251 Hart Dec 1998 A
5860938 Lafontaine et al. Jan 1999 A
5873866 Kondo et al. Feb 1999 A
5873882 Straub et al. Feb 1999 A
5876414 Straub Mar 1999 A
5895406 Gray et al. Apr 1999 A
5908435 Samuels Jun 1999 A
5911710 Barry et al. Jun 1999 A
5911733 Parodi Jun 1999 A
5911754 Kanesaka et al. Jun 1999 A
5941869 Patterson et al. Aug 1999 A
5947985 Imran Sep 1999 A
5954737 Lee Sep 1999 A
5971938 Hart et al. Oct 1999 A
5972019 Engelson et al. Oct 1999 A
5974938 Lloyd Nov 1999 A
5989233 Yoon Nov 1999 A
5993483 Gianotti Nov 1999 A
6030397 Moneti et al. Feb 2000 A
6066158 Engelson et al. May 2000 A
6068645 Tu May 2000 A
6126635 Simpson et al. Oct 2000 A
6142987 Tsugita Nov 2000 A
6146396 Konya et al. Nov 2000 A
6146403 St. Germain Nov 2000 A
6152946 Broome et al. Nov 2000 A
6156055 Ravenscroft Dec 2000 A
6159230 Samuels Dec 2000 A
6165196 Stack et al. Dec 2000 A
6168579 Tsugita Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6228060 Howell May 2001 B1
6238412 Dubrul et al. May 2001 B1
6245078 Ouchi Jun 2001 B1
6245089 Daniel et al. Jun 2001 B1
6254571 Hart Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6264663 Cano Jul 2001 B1
6306163 Fitz Oct 2001 B1
6322572 Lee Nov 2001 B1
6350271 Kurz et al. Feb 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6364895 Greenhalgh Apr 2002 B1
6368339 Amplatz Apr 2002 B1
6383205 Samson et al. May 2002 B1
6402771 Palmer et al. Jun 2002 B1
6413235 Parodi Jul 2002 B1
6423032 Parodi Jul 2002 B2
6432122 Gilson et al. Aug 2002 B1
6451036 Heitzmann et al. Sep 2002 B1
6458103 Albert et al. Oct 2002 B1
6475236 Roubin et al. Nov 2002 B1
6485502 Don Michael Nov 2002 B2
6508782 Evans et al. Jan 2003 B1
6511492 Rosenbluth et al. Jan 2003 B1
6514273 Voss et al. Feb 2003 B1
6530923 Dubrul et al. Mar 2003 B1
6530935 Wensel et al. Mar 2003 B2
6544276 Azizi Apr 2003 B1
6544278 Vrba et al. Apr 2003 B1
6544279 Hopkins et al. Apr 2003 B1
6551342 Shen et al. Apr 2003 B1
6564828 Ishida May 2003 B1
6569181 Burns May 2003 B1
6575995 Huter et al. Jun 2003 B1
6589263 Hopkins et al. Jul 2003 B1
6596011 Johnson et al. Jul 2003 B2
6602271 Adams et al. Aug 2003 B2
6605074 Zadno-Azizi et al. Aug 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6620148 Tsugita Sep 2003 B1
6620179 Brook et al. Sep 2003 B2
6620182 Khosravi et al. Sep 2003 B1
6623460 Heck Sep 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6645222 Parodi et al. Nov 2003 B1
6660013 Rabiner et al. Dec 2003 B2
6660014 Demarais et al. Dec 2003 B2
6663650 Sepetka et al. Dec 2003 B2
6692504 Kurz et al. Feb 2004 B2
6699260 Dubrul et al. Mar 2004 B2
6702830 Demarais et al. Mar 2004 B1
6719717 Johnson et al. Apr 2004 B1
6755847 Eskuri Jun 2004 B2
6767353 Shiber Jul 2004 B1
6790204 Zadno-azizi et al. Sep 2004 B2
6800080 Bates Oct 2004 B1
6818006 Douk et al. Nov 2004 B2
6824545 Sepetka et al. Nov 2004 B2
6824550 Noriega et al. Nov 2004 B1
6824553 Gene et al. Nov 2004 B1
6830561 Jansen et al. Dec 2004 B2
6846029 Ragner et al. Jan 2005 B1
6902540 Dorros et al. Jun 2005 B2
6939361 Kleshinski Sep 2005 B1
6942682 Vrba et al. Sep 2005 B2
6945977 Demarais et al. Sep 2005 B2
6960189 Bates et al. Nov 2005 B2
6960222 Vo et al. Nov 2005 B2
7004931 Hogendijk Feb 2006 B2
7004954 Voss et al. Feb 2006 B1
7036707 Aota et al. May 2006 B2
7041084 Fotjik May 2006 B2
7052500 Bashiri et al. May 2006 B2
7056328 Arnott Jun 2006 B2
7063707 Bose et al. Jun 2006 B2
7069835 Nishri et al. Jul 2006 B2
7094249 Thomas et al. Aug 2006 B1
7179273 Palmer et al. Feb 2007 B1
7223253 Hogendijk May 2007 B2
7232432 Fulton, III et al. Jun 2007 B2
7244243 Lary Jul 2007 B2
7285126 Sepetka et al. Oct 2007 B2
7300458 Henkes et al. Nov 2007 B2
7306618 Demond et al. Dec 2007 B2
7320698 Eskuri Jan 2008 B2
7323002 Johnson et al. Jan 2008 B2
7331980 Dubrul et al. Feb 2008 B2
7534234 Fotjik May 2009 B2
7578830 Kusleika et al. Aug 2009 B2
7621870 Berrada et al. Nov 2009 B2
7674247 Fotjik Mar 2010 B2
7691121 Rosenbluth et al. Apr 2010 B2
7695458 Belley et al. Apr 2010 B2
7763010 Evans et al. Jul 2010 B2
7766934 Pal et al. Aug 2010 B2
7775501 Kees Aug 2010 B2
7780696 Daniel et al. Aug 2010 B2
7905877 Oscar et al. Mar 2011 B1
7905896 Straub Mar 2011 B2
7938809 Lampropoulos et al. May 2011 B2
7938820 Webster et al. May 2011 B2
7967790 Whiting et al. Jun 2011 B2
7976511 Fotjik Jul 2011 B2
7993302 Hebert et al. Aug 2011 B2
7993363 Demond et al. Aug 2011 B2
8043313 Krolik et al. Oct 2011 B2
8052640 Fiorella et al. Nov 2011 B2
8057496 Fischer, Jr. Nov 2011 B2
8057497 Raju et al. Nov 2011 B1
8066757 Ferrera et al. Nov 2011 B2
8070769 Broome Dec 2011 B2
8070791 Ferrera et al. Dec 2011 B2
8075510 Aklog et al. Dec 2011 B2
8088140 Ferrera et al. Jan 2012 B2
8092486 Berrada et al. Jan 2012 B2
8100935 Rosenbluth et al. Jan 2012 B2
8109962 Pal Feb 2012 B2
8118829 Carrison et al. Feb 2012 B2
8197493 Ferrera et al. Jun 2012 B2
8246641 Osborne et al. Aug 2012 B2
8261648 Marchand et al. Sep 2012 B1
8267897 Wells Sep 2012 B2
8298257 Sepetka et al. Oct 2012 B2
8317748 Fiorella et al. Nov 2012 B2
8337450 Fotjik Dec 2012 B2
RE43902 Hopkins et al. Jan 2013 E
8357178 Grandfield et al. Jan 2013 B2
8361104 Jones et al. Jan 2013 B2
8409215 Sepetka et al. Apr 2013 B2
8486105 Demond et al. Jul 2013 B2
8491539 Fotjik Jul 2013 B2
8512352 Martin Aug 2013 B2
8535283 Heaton et al. Sep 2013 B2
8535334 Martin Sep 2013 B2
8545526 Martin et al. Oct 2013 B2
8568432 Straub Oct 2013 B2
8574262 Ferrera et al. Nov 2013 B2
8579915 French et al. Nov 2013 B2
8585713 Ferrera et al. Nov 2013 B2
8608754 Wensel et al. Dec 2013 B2
8657867 Dorn et al. Feb 2014 B2
8696622 Fiorella et al. Apr 2014 B2
8715314 Janardhan et al. May 2014 B1
8721714 Kelley May 2014 B2
8753322 Hu et al. Jun 2014 B2
8771289 Mohiuddin et al. Jul 2014 B2
8777893 Malewicz Jul 2014 B2
8784441 Rosenbluth et al. Jul 2014 B2
8784442 Jones et al. Jul 2014 B2
8795305 Martin et al. Aug 2014 B2
8795345 Grandfield et al. Aug 2014 B2
8801748 Martin Aug 2014 B2
8808259 Walton et al. Aug 2014 B2
8814927 Shin et al. Aug 2014 B2
8820207 Marchand et al. Sep 2014 B2
8826791 Thompson et al. Sep 2014 B2
8828044 Aggerholm et al. Sep 2014 B2
8833224 Thompson et al. Sep 2014 B2
8845621 Fotjik Sep 2014 B2
8852226 Gilson et al. Oct 2014 B2
8939991 Krolik et al. Jan 2015 B2
8945143 Ferrera et al. Feb 2015 B2
8945172 Ferrera et al. Feb 2015 B2
8956384 Berrada et al. Feb 2015 B2
8992504 Castella et al. Mar 2015 B2
9005172 Chung Apr 2015 B2
9028401 Bacich et al. May 2015 B1
9078682 Lenker et al. Jul 2015 B2
9101382 Krolik et al. Aug 2015 B2
9125683 Farhangnia et al. Sep 2015 B2
9126016 Fulton Sep 2015 B2
9149609 Ansel et al. Oct 2015 B2
9155552 Ulm, III Oct 2015 B2
9161766 Slee et al. Oct 2015 B2
9173668 Ulm, III Nov 2015 B2
9186487 Dubrul et al. Nov 2015 B2
9204887 Cully et al. Dec 2015 B2
9216277 Myers Dec 2015 B2
9358037 Farhangnia et al. Jan 2016 B2
9259237 Quick et al. Feb 2016 B2
9283066 Hopkins et al. Mar 2016 B2
9351747 Kugler et al. May 2016 B2
9439664 Sos Sep 2016 B2
9439751 White et al. Sep 2016 B2
9456834 Folk Oct 2016 B2
9463035 Greenhalgh et al. Oct 2016 B1
9463036 Brady et al. Oct 2016 B2
9526864 Quick Dec 2016 B2
9526865 Quick Dec 2016 B2
9566424 Pessin Feb 2017 B2
9579116 Nguyen et al. Feb 2017 B1
9616213 Furnish et al. Apr 2017 B2
9636206 Nguyen et al. May 2017 B2
9643035 Mastenbroek May 2017 B2
9700332 Marchand et al. Jul 2017 B2
9717514 Martin et al. Aug 2017 B2
9717519 Rosenbluth et al. Aug 2017 B2
9744024 Nguyen et al. Aug 2017 B2
9757137 Krolik et al. Sep 2017 B2
9827084 Bonnette et al. Nov 2017 B2
9844386 Nguyen et al. Dec 2017 B2
9844387 Marchand et al. Dec 2017 B2
9848975 Hauser Dec 2017 B2
9849014 Kusleika Dec 2017 B2
9962178 Greenhalgh et al. May 2018 B2
9980813 Eller May 2018 B2
9999493 Nguyen et al. Jun 2018 B2
10004531 Rosenbluth et al. Jun 2018 B2
10010335 Greenhalgh et al. Jul 2018 B2
10016266 Hauser Jul 2018 B2
10028759 Wallace et al. Jul 2018 B2
10045790 Cox et al. Aug 2018 B2
10098651 Marchand et al. Oct 2018 B2
10130385 Farhangnia et al. Nov 2018 B2
10226263 Look et al. Mar 2019 B2
10238406 Cox et al. Mar 2019 B2
10271864 Greenhalgh et al. Apr 2019 B2
10327883 Yachia Jun 2019 B2
10335186 Rosenbluth et al. Jul 2019 B2
10342571 Marchand et al. Jul 2019 B2
10349960 Quick Jul 2019 B2
10383644 Molaei et al. Aug 2019 B2
10478535 Ogle Nov 2019 B2
10524811 Marchand et al. Jan 2020 B2
10588655 Rosenbluth et al. Mar 2020 B2
10695159 Hauser Jun 2020 B2
10709471 Rosenbluth et al. Jul 2020 B2
10799331 Hauser Oct 2020 B2
10912577 Marchand et al. Feb 2021 B2
11000682 Merritt et al. May 2021 B2
11013523 Arad Hadar May 2021 B2
11058445 Cox et al. Jul 2021 B2
11058451 Marchand et al. Jul 2021 B2
11147571 Cox et al. Oct 2021 B2
11154314 Quick Oct 2021 B2
11259821 Buck et al. Mar 2022 B2
11406801 Fojtik et al. Aug 2022 B2
11433218 Quick et al. Sep 2022 B2
11439799 Buck et al. Sep 2022 B2
11457936 Buck et al. Oct 2022 B2
11529158 Hauser Dec 2022 B2
11554005 Merritt et al. Jan 2023 B2
11559382 Merritt et al. Jan 2023 B2
20010004699 Gittings et al. Jun 2001 A1
20010041909 Tsugita et al. Nov 2001 A1
20010049486 Evans et al. Dec 2001 A1
20010051810 Dubrul et al. Dec 2001 A1
20020022858 Demond et al. Feb 2002 A1
20020022859 Hogendijk Feb 2002 A1
20020026211 Khosravi et al. Feb 2002 A1
20020032455 Boock et al. Mar 2002 A1
20020049452 Kurz et al. Apr 2002 A1
20020095161 Dhindsa Jul 2002 A1
20020095171 Belef Jul 2002 A1
20020111648 Kusleika et al. Aug 2002 A1
20020120277 Hauschild et al. Aug 2002 A1
20020147458 Hiblar et al. Oct 2002 A1
20020151918 Lafontaine et al. Oct 2002 A1
20020156457 Fisher Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020169474 Kusleika Nov 2002 A1
20020173819 Leeflang et al. Nov 2002 A1
20020188276 Evans et al. Dec 2002 A1
20030083693 Daniel et al. May 2003 A1
20030100919 Hopkins et al. May 2003 A1
20030114875 Sjostrom Jun 2003 A1
20030116731 Hartley Jun 2003 A1
20030125663 Coleman et al. Jul 2003 A1
20030135230 Massey et al. Jul 2003 A1
20030135258 Andreas et al. Jul 2003 A1
20030153873 Luther et al. Aug 2003 A1
20030153973 Soun et al. Aug 2003 A1
20030168068 Poole et al. Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030191516 Weldon et al. Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030216774 Larson Nov 2003 A1
20040039412 Isshiki et al. Feb 2004 A1
20040068288 Palmer et al. Apr 2004 A1
20040073243 Sepetka et al. Apr 2004 A1
20040098033 Leeflang et al. May 2004 A1
20040122359 Wenz et al. Jun 2004 A1
20040127936 Salahieh et al. Jul 2004 A1
20040133232 Rosenbluth et al. Jul 2004 A1
20040138525 Saadat et al. Jul 2004 A1
20040138692 Phung et al. Jul 2004 A1
20040167567 Cano et al. Aug 2004 A1
20040199201 Kellett et al. Oct 2004 A1
20040199202 Dubrul et al. Oct 2004 A1
20040260344 Lyons et al. Dec 2004 A1
20040267272 Henniges et al. Dec 2004 A1
20050033172 Dubrul et al. Feb 2005 A1
20050038468 Panetta et al. Feb 2005 A1
20050054995 Barzell et al. Mar 2005 A1
20050055047 Greenhalgh Mar 2005 A1
20050085769 MacMahon et al. Apr 2005 A1
20050085826 Nair et al. Apr 2005 A1
20050085846 Carrison et al. Apr 2005 A1
20050085849 Sepetka et al. Apr 2005 A1
20050119668 Teague et al. Jun 2005 A1
20050177132 Lentz et al. Aug 2005 A1
20050187570 Nguyen et al. Aug 2005 A1
20050283165 Gadberry Dec 2005 A1
20050283166 Greenhalgh et al. Dec 2005 A1
20050283186 Berrada et al. Dec 2005 A1
20060020286 Niermann Jan 2006 A1
20060042786 West Mar 2006 A1
20060047286 West Mar 2006 A1
20060074401 Ross Apr 2006 A1
20060089533 Ziegler et al. Apr 2006 A1
20060100662 Daniel et al. May 2006 A1
20060155305 Freudenthal et al. Jul 2006 A1
20060173525 Behl et al. Aug 2006 A1
20060195137 Sepetka et al. Aug 2006 A1
20060200221 Malewicz Sep 2006 A1
20060217664 Hattler et al. Sep 2006 A1
20060224177 Finitsis Oct 2006 A1
20060229645 Bonnette et al. Oct 2006 A1
20060247500 Voegele et al. Nov 2006 A1
20060253145 Lucas Nov 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20060282111 Morsi Dec 2006 A1
20060293696 Fahey et al. Dec 2006 A1
20070010787 Hackett et al. Jan 2007 A1
20070038225 Osborne Feb 2007 A1
20070093744 Elmaleh Apr 2007 A1
20070112374 Paul, Jr. et al. May 2007 A1
20070118165 DeMello et al. May 2007 A1
20070149996 Coughlin Jun 2007 A1
20070161963 Smalling Jul 2007 A1
20070179513 Deutsch Aug 2007 A1
20070191866 Palmer et al. Aug 2007 A1
20070198028 Miloslavski et al. Aug 2007 A1
20070208361 Okushi et al. Sep 2007 A1
20070208367 Fiorella et al. Sep 2007 A1
20070213753 Waller Sep 2007 A1
20070213765 Adams et al. Sep 2007 A1
20070255252 Mehta Nov 2007 A1
20070288054 Tanaka et al. Dec 2007 A1
20080015541 Rosenbluth et al. Jan 2008 A1
20080088055 Ross Apr 2008 A1
20080157017 Macatangay et al. Jul 2008 A1
20080167678 Morsi Jul 2008 A1
20080183136 Lenker et al. Jul 2008 A1
20080228209 DeMello et al. Sep 2008 A1
20080234715 Pesce et al. Sep 2008 A1
20080234722 Bonnette et al. Sep 2008 A1
20080262528 Martin Oct 2008 A1
20080269798 Ramzipoor et al. Oct 2008 A1
20080300466 Gresham Dec 2008 A1
20090018566 Escudero et al. Jan 2009 A1
20090054918 Henson Feb 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090069828 Martin et al. Mar 2009 A1
20090076417 Jones Mar 2009 A1
20090160112 Ostrovsky Jun 2009 A1
20090163846 Aklog et al. Jun 2009 A1
20090182362 Thompson et al. Jul 2009 A1
20090192495 Ostrovsky et al. Jul 2009 A1
20090281525 Harding et al. Nov 2009 A1
20090292307 Razack Nov 2009 A1
20090299393 Martin et al. Dec 2009 A1
20100016837 Howat Jan 2010 A1
20100030256 Dubrul et al. Feb 2010 A1
20100042136 Berrada et al. Feb 2010 A1
20100087844 Fischer, Jr. Apr 2010 A1
20100087850 Razack Apr 2010 A1
20100114113 Dubrul et al. May 2010 A1
20100121312 Gielenz et al. May 2010 A1
20100137846 Desai et al. Jun 2010 A1
20100190156 Van Wordragen et al. Jul 2010 A1
20100204712 Mallaby Aug 2010 A1
20100217276 Garrison et al. Aug 2010 A1
20100249815 Jantzen et al. Sep 2010 A1
20100268264 Bonnette et al. Oct 2010 A1
20100318178 Rapaport et al. Dec 2010 A1
20110034986 Chou et al. Feb 2011 A1
20110034987 Kennedy Feb 2011 A1
20110054405 Whiting et al. Mar 2011 A1
20110060212 Slee et al. Mar 2011 A1
20110118817 Gunderson et al. May 2011 A1
20110125181 Brady et al. May 2011 A1
20110144592 Wong et al. Jun 2011 A1
20110152823 Mohiuddin et al. Jun 2011 A1
20110152993 Marchand et al. Jun 2011 A1
20110160742 Ferrera et al. Jun 2011 A1
20110160763 Ferrera et al. Jun 2011 A1
20110190806 Wittens Aug 2011 A1
20110196309 Wells Aug 2011 A1
20110196414 Porter et al. Aug 2011 A1
20110213290 Chin et al. Sep 2011 A1
20110213403 Aboytes Sep 2011 A1
20110224707 Miloslavski et al. Sep 2011 A1
20110245807 Sakata et al. Oct 2011 A1
20110251629 Galdonik et al. Oct 2011 A1
20110264133 Hanlon et al. Oct 2011 A1
20110265681 Allen et al. Nov 2011 A1
20110288529 Fulton Nov 2011 A1
20110288572 Martin Nov 2011 A1
20110319917 Ferrera et al. Dec 2011 A1
20120059309 di Palma et al. Mar 2012 A1
20120059356 di Palma et al. Mar 2012 A1
20120083824 Berrada et al. Apr 2012 A1
20120083868 Shrivastava Apr 2012 A1
20120089216 Rapaport et al. Apr 2012 A1
20120101480 Ingle et al. Apr 2012 A1
20120101510 Lenker et al. Apr 2012 A1
20120138832 Townsend Jun 2012 A1
20120143239 Aklog et al. Jun 2012 A1
20120165919 Cox et al. Jun 2012 A1
20120172918 Fifer et al. Jul 2012 A1
20120179181 Straub et al. Jul 2012 A1
20120197277 Stinis Aug 2012 A1
20120232655 Lorrison et al. Sep 2012 A1
20120271105 Nakamura et al. Oct 2012 A1
20120271231 Agrawal Oct 2012 A1
20120277788 Cattaneo Nov 2012 A1
20120310166 Huff Dec 2012 A1
20130030460 Marks et al. Jan 2013 A1
20130035628 Garrison et al. Feb 2013 A1
20130046332 Jones et al. Feb 2013 A1
20130066348 Fiorella et al. Mar 2013 A1
20130092012 Marchand et al. Apr 2013 A1
20130096571 Massicotte et al. Apr 2013 A1
20130102996 Strauss Apr 2013 A1
20130116708 Ziniti et al. May 2013 A1
20130116721 Takagi et al. May 2013 A1
20130126559 Cowan et al. May 2013 A1
20130144326 Brady et al. Jun 2013 A1
20130165871 Fiorella et al. Jun 2013 A1
20130184703 Shireman et al. Jul 2013 A1
20130197454 Shibata et al. Aug 2013 A1
20130197567 Brady et al. Aug 2013 A1
20130226196 Smith Aug 2013 A1
20130281788 Garrison Oct 2013 A1
20130289608 Tanaka et al. Oct 2013 A1
20130317589 Martin et al. Nov 2013 A1
20130345739 Brady et al. Dec 2013 A1
20140005712 Martin Jan 2014 A1
20140005713 Bowman Jan 2014 A1
20140005715 Castella et al. Jan 2014 A1
20140005717 Martin et al. Jan 2014 A1
20140025048 Ward Jan 2014 A1
20140031856 Martin Jan 2014 A1
20140046133 Nakamura et al. Feb 2014 A1
20140046243 Ray et al. Feb 2014 A1
20140052161 Cully et al. Feb 2014 A1
20140074144 Shrivastava et al. Mar 2014 A1
20140121672 Folk May 2014 A1
20140155830 Bonnette et al. Jun 2014 A1
20140155980 Turjman Jun 2014 A1
20140180397 Gerberding et al. Jun 2014 A1
20140155908 Rosenbluth et al. Jul 2014 A1
20140188127 Dubrul et al. Jul 2014 A1
20140188143 Martin et al. Jul 2014 A1
20140236219 Dubrul et al. Aug 2014 A1
20140243882 Ma Aug 2014 A1
20140257253 Jemison Sep 2014 A1
20140257363 Lippert Sep 2014 A1
20140276403 Follmer et al. Sep 2014 A1
20140296868 Garrison et al. Oct 2014 A1
20140303658 Bonnette et al. Oct 2014 A1
20140318354 Thompson et al. Oct 2014 A1
20140324091 Rosenbluth Oct 2014 A1
20140330286 Wallace et al. Nov 2014 A1
20140336691 Jones et al. Nov 2014 A1
20140343593 Chin et al. Nov 2014 A1
20140364896 Consigny Dec 2014 A1
20140371779 Vale et al. Dec 2014 A1
20150005781 Lund-Clausen et al. Jan 2015 A1
20150005792 Ahn Jan 2015 A1
20150018859 Quick Jan 2015 A1
20150018860 Quick Jan 2015 A1
20150018929 Martin et al. Jan 2015 A1
20150025555 Sos Jan 2015 A1
20150032144 Holloway Jan 2015 A1
20150059908 Mollen Mar 2015 A1
20150088190 Jensen Mar 2015 A1
20150127035 Trapp et al. May 2015 A1
20150133990 Davidson May 2015 A1
20150150672 Ma Jun 2015 A1
20150164523 Brady et al. Jun 2015 A1
20150164666 Johnson et al. Jun 2015 A1
20150173782 Garrison et al. Jun 2015 A1
20150190155 Ulm, III Jul 2015 A1
20150190156 Ulm, III Jul 2015 A1
20150196380 Berrada et al. Jul 2015 A1
20150196744 Aboytes Jul 2015 A1
20150209058 Ferrera et al. Jul 2015 A1
20150209165 Grandfield et al. Jul 2015 A1
20150238207 Cox et al. Aug 2015 A1
20150250578 Cook et al. Sep 2015 A1
20150265299 Cooper et al. Sep 2015 A1
20150305756 Rosenbluth Oct 2015 A1
20150305859 Eller Oct 2015 A1
20150352325 Quick Dec 2015 A1
20150360001 Quick Dec 2015 A1
20150374391 Quick Dec 2015 A1
20160022293 Dubrul et al. Jan 2016 A1
20160058540 Don Michael Mar 2016 A1
20160074627 Cottone Mar 2016 A1
20160106448 Brady et al. Apr 2016 A1
20160106449 Brady et al. Apr 2016 A1
20160113663 Brady et al. Apr 2016 A1
20160113664 Brady et al. Apr 2016 A1
20160113665 Brady et al. Apr 2016 A1
20160113666 Quick Apr 2016 A1
20160143721 Rosenbluth May 2016 A1
20160151605 Welch et al. Jun 2016 A1
20160206344 Bruzzi et al. Jul 2016 A1
20160008014 Rosenbluth Aug 2016 A1
20160220741 Garrison et al. Aug 2016 A1
20160228134 Martin et al. Aug 2016 A1
20160262774 Honda Sep 2016 A1
20160262790 Rosenbluth et al. Sep 2016 A1
20160287276 Cox et al. Oct 2016 A1
20160367285 Sos Dec 2016 A1
20170014560 Minskoff et al. Jan 2017 A1
20170037548 Lee Feb 2017 A1
20170042571 Levi Feb 2017 A1
20170049942 Conlan et al. Feb 2017 A1
20170056032 Look et al. Mar 2017 A1
20170058623 Jaffrey et al. Mar 2017 A1
20170079672 Quick Mar 2017 A1
20170086864 Greenhalgh et al. Mar 2017 A1
20170100142 Look et al. Apr 2017 A1
20170105743 Vale et al. Apr 2017 A1
20170105745 Rosenbluth et al. Apr 2017 A1
20170112514 Marchand et al. Apr 2017 A1
20170112513 Marchand et al. Jul 2017 A1
20170189041 Cox et al. Jul 2017 A1
20170196576 Long et al. Jul 2017 A1
20170233908 Kroczynski et al. Aug 2017 A1
20170252057 Bonnette et al. Sep 2017 A1
20170265878 Marchand et al. Sep 2017 A1
20170303939 Greenhalgh et al. Oct 2017 A1
20170303942 Greenhalgh et al. Oct 2017 A1
20170303947 Greenhalgh et al. Oct 2017 A1
20170303948 Wallace et al. Oct 2017 A1
20170319221 Chu Nov 2017 A1
20170325839 Rosenbluth et al. Nov 2017 A1
20170340867 Accisano, II Nov 2017 A1
20170348014 Wallace et al. Dec 2017 A1
20180042623 Batiste Feb 2018 A1
20180042624 Greenhalgh et al. Feb 2018 A1
20180042626 Greenhalgh et al. Feb 2018 A1
20180064453 Garrison et al. Mar 2018 A1
20180064454 Losordo et al. Mar 2018 A1
20180070968 Wallace et al. Mar 2018 A1
20180092652 Marchand et al. Apr 2018 A1
20180104404 Ngo-Chu Apr 2018 A1
20180105963 Quick Apr 2018 A1
20180125512 Nguyen et al. May 2018 A1
20180184912 Al-Ali Jul 2018 A1
20180193043 Marchand et al. Jul 2018 A1
20180236205 Krautkremer et al. Aug 2018 A1
20180256177 Cooper et al. Sep 2018 A1
20180256178 Cox et al. Sep 2018 A1
20180296240 Rosenbluth et al. Oct 2018 A1
20180344339 Cox et al. Dec 2018 A1
20180361116 Quick et al. Dec 2018 A1
20190000492 Casey et al. Jan 2019 A1
20190046219 Marchand et al. Feb 2019 A1
20190070401 Merritt et al. Mar 2019 A1
20190117244 Wallace et al. Apr 2019 A1
20190133622 Wallace et al. May 2019 A1
20190133623 Wallace et al. May 2019 A1
20190133624 Wallace et al. May 2019 A1
20190133625 Wallace et al. May 2019 A1
20190133626 Wallace et al. May 2019 A1
20190133627 Wallace et al. May 2019 A1
20190150959 Cox et al. May 2019 A1
20190231373 Quick Aug 2019 A1
20190239910 Brady et al. Aug 2019 A1
20190321071 Marchand et al. Oct 2019 A1
20190336142 Torrie et al. Nov 2019 A1
20190336148 Greenhalgh et al. Nov 2019 A1
20200046368 Merritt et al. Feb 2020 A1
20200113412 Jensen Apr 2020 A1
20210022843 Hauser Jan 2021 A1
20210113224 Dinh Apr 2021 A1
20210137667 Sonnette et al. May 2021 A1
20210186541 Thress Jun 2021 A1
20210236148 Marchand et al. Aug 2021 A1
20210290925 Merritt et al. Sep 2021 A1
20210315598 Buck et al. Oct 2021 A1
20210378694 Thress et al. Dec 2021 A1
20220000505 Hauser Jan 2022 A1
20220000506 Hauser Jan 2022 A1
20220000507 Hauser Jan 2022 A1
20220015798 Marchand et al. Jan 2022 A1
20220022898 Cox et al. Jan 2022 A1
20220039815 Thress et al. Feb 2022 A1
20220125451 Hauser Apr 2022 A1
20220142638 Enright et al. May 2022 A1
20220151647 Dolendo et al. May 2022 A1
20220152355 Dolendo et al. May 2022 A1
20220160381 Hauser May 2022 A1
20220160382 Hauser May 2022 A1
20220160383 Hauser May 2022 A1
20220211400 Cox et al. Jul 2022 A1
20220211992 Merritt et al. Jul 2022 A1
20220240959 Quick Aug 2022 A1
20220346800 Merritt et al. Nov 2022 A1
20220346801 Merritt et al. Nov 2022 A1
20220346813 Quick Nov 2022 A1
20220346814 Quick Nov 2022 A1
20220347455 Merritt et al. Nov 2022 A1
20220362512 Quick et al. Nov 2022 A1
20230046775 Quick Feb 2023 A1
20230062809 Merritt et al. Mar 2023 A1
Foreign Referenced Citations (89)
Number Date Country
2015210338 Aug 2015 AU
102186427 Sep 2011 CN
103764049 Apr 2014 CN
103932756 Jul 2014 CN
104068910 Oct 2014 CN
108348319 Jul 2018 CN
110652645 Jan 2020 CN
111281482 Jun 2020 CN
102017004383 Jul 2018 DE
1254634 Nov 2002 EP
1867290 Feb 2013 EP
1588072 Apr 1981 GB
2498349 Jul 2013 GB
H6190049 Jul 1994 JP
H07323090 Dec 1995 JP
2001522631 May 1999 JP
2004097807 Apr 2004 JP
2005-095242 Jun 2005 JP
2005230132 Sep 2005 JP
2005323702 Nov 2005 JP
2006094876 Apr 2006 JP
2011526820 Jan 2010 JP
WO1997017889 May 1997 WO
WO9833443 Aug 1998 WO
WO9838920 Sep 1998 WO
WO9839053 Sep 1998 WO
WO9851237 Nov 1998 WO
WO1999044542 Sep 1999 WO
WO0032118 Jun 2000 WO
WO2000053120 Sep 2000 WO
WO0202162 Jan 2002 WO
WO03015840 Feb 2003 WO
WO2004018916 Mar 2004 WO
WO2004093696 Nov 2004 WO
WO2005046736 May 2005 WO
WO2006110186 Oct 2006 WO
WO2006124307 Nov 2006 WO
WO2007092820 Aug 2007 WO
WO2009082513 Jul 2009 WO
WO2009086482 Jul 2009 WO
WO2009155571 Dec 2009 WO
WO2010002549 Jan 2010 WO
WO2010010545 Jan 2010 WO
WO2010023671 Mar 2010 WO
WO2010049121 May 2010 WO
WO2010102307 Sep 2010 WO
WO2011032712 Mar 2011 WO
WO2011054531 May 2011 WO
WO2011073176 Jun 2011 WO
WO2012009675 Jan 2012 WO
WO2012011097 Jan 2012 WO
WO2012049652 Apr 2012 WO
WO2012065748 May 2012 WO
WO2012120490 Sep 2012 WO
WO2012162437 Nov 2012 WO
WO2014047650 Mar 2014 WO
WO2014081892 May 2014 WO
WO2015006782 Jan 2015 WO
WO2015061365 Apr 2015 WO
WO2015121424 Aug 2015 WO
WO2015189354 Dec 2015 WO
WO2015191646 Dec 2015 WO
WO2017024258 Feb 2017 WO
WO2017058280 Apr 2017 WO
WO2017070702 Apr 2017 WO
WO2017106877 Jun 2017 WO
WO2017189535 Nov 2017 WO
WO2017189550 Nov 2017 WO
WO2017189591 Nov 2017 WO
WO2017189615 Nov 2017 WO
WO2017210487 Dec 2017 WO
WO2018049317 Mar 2018 WO
WO2018080590 May 2018 WO
WO2018148174 Aug 2018 WO
WO2019010318 Jan 2019 WO
WO2019050765 Mar 2019 WO
WO2019075444 Apr 2019 WO
WO2019094456 May 2019 WO
WO2019222117 Nov 2019 WO
WO2019246240 Dec 2019 WO
WO2020036809 Feb 2020 WO
WO2021067134 Apr 2021 WO
WO2021076954 Apr 2021 WO
WO2021127202 Jun 2021 WO
WO2021248042 Dec 2021 WO
WO2022032173 Feb 2022 WO
WO2022103848 May 2022 WO
WO2022109021 May 2022 WO
WO2022109034 May 2022 WO
Non-Patent Literature Citations (85)
Entry
European Patent Application No. 13838945.7, Extended European Search Report, 9 pages, dated Apr. 15, 2016.
Gibbs, et al., “Temporary Stent as a bail-out device during percutaneous transluminal coronary angioplasty: preliminary clinical experience,” British Heart Journal, 1994, 71:372-377, Oct. 12, 1993 6 pgs.
Gupta, S. et al., “Acute Pulmonary Embolism Advances in Treatment”, JAPI, Association of Physicians India, Mar. 2008, vol. 56, 185-191.
International Search Report and Written Opinion for International App. No. PCT/US13/61470, dated Jan. 17, 2014, 7 pages.
International Search Report and Written Opinion for International App. No. PCT/US2014/046567, dated Nov. 3, 2014, 13 pages.
International Search Report and Written Opinion for International App. No. PCT/US2014/061645, dated Jan. 23, 2015, 15 pages.
International Search Report for International App. No. PCT/US13/71101, dated Mar. 31, 2014, 4 pages.
Konstantinides, S. et al., “Pulmonary embolism hotline 2012—Recent and expected trials”, Thrombosis and Haemostasis, Jan. 9, 2013:33; 43-50.
Konstantinides, S. et al., “Pulmonary embolism: risk assessment and management”, European Society of Cardiology; European Heart Journal, Sep. 7, 2012:33, 3014-3022.
Kucher, N. et al., “Percutaneous Catheter Thrombectomy Device for Acute Pulmonary Embolism: In Vitro and in Vivo Testing”, Circulation, Sep. 2005:112:e28-e32.
Kucher, N., “Catheter Interventions in Massive Pulmonary Embolism”, Cardiology Rounds, Mar. 2006 vol. 10, Issue 3, 6 pages.
Kucher, N. et al., “Management of Massive Pulmonary Embolism”, Radiology, Sep. 2005:236:3852-858.
Kucher, N. et al., “Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism.” Circulation, 2014, 129, p. 9 pages.
Kuo, W. et al., “Catheter-directed Therapy for the Treatment of Massive Pulmonary Embolism: Systematic Review and Meta-analysis of Modern Techniques”, Journal of Vascular and Interventional Radiology, Nov. 2009:20:1431-1440.
Kuo, W. et al., “Catheter-Directed Embolectomy, Fragmentation, and Thrombolysis for the Treatment of Massive Pulmonary Embolism After Failure of Systemic Thrombolysis”, American College of CHEST Physicians 2008: 134:250-254.
Kuo, W. MD, “Endovascular Therapy for Acute Pulmonary Embolism”, Continuing Medical Education Society of Interventional Radiology (“CME”); Journal of Vascular and Interventional Radiology, Feb. 2012: 23:167-179.
Lee, L. et al., “Massive pulmonary embolism: review of management strategies with a focus on catheter-based techniques”, Expert Rev. Cardiovasc. Ther. 8(6), 863-873 (2010).
Liu, S. et al., “Massive Pulmonary Embolism: Treatment with the Rotarex Thrombectomy System”, Cardiovascular Interventional Radiology; 2011: 34:106-113.
Muller-Hulsbeck, S. et al. “Mechanical Thrombectomy of Major and Massive Pulmonary Embolism with Use of the Amplatz Thrombectomy Device”, Investigative Radiology, Jun. 2001:36:6:317-322.
Reekers, J. et al., “Mechanical Thrombectomy for Early Treatment of Massive Pulmonary Embolism”, Cardiovascular and Interventional Radiology, 2003: 26:246-250.
Schmitz-Rode et al., “New Mesh Basket for Percutaneous Removal of Wall-Adherent Thrombi in Dialysis Shunts,” Cardiovasc Intervent Radiol 16:7-10 1993 4 pgs.
Schmitz-Rode et al., “Temporary Pulmonary Stent Placement as Emergency Treatment of Pulmonary Embolism,” Journal of the American College of Cardiology, vol. 48, No. 4, 2006 (5 pgs.).
Schmitz-Rode, T. et al., “Massive Pulmonary Embolism: Percutaneous Emergency Treatment by Pigtail Rotation Catheter”, JACC Journal of the American College of Cardiology, Aug. 2000:36:2:375-380.
Spiotta, A et al., “Evolution of thrombectomy approaches and devices for acute stroke: a technical review.” J NeuroIntervent Surg 2015, 7, p. 7 pages.
Svilaas, T. et al., “Thrombus Aspiration During Primary Percutaneous Coronary Intervention.” The New England Journal of Medicine, 2008, vol. 358, No. 6, 11 pages.
Tapson, V., “Acute Pulmonary Embolism”, The New England Journal of Medicine, Mar. 6, 2008:358:2037-52.
The Penumbra Pivotal Stroke Trial Investigators, “The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease.” Stroke, 2009, 40: p. 9 pages.
Truong et al., “Mechanical Thrombectomy of Iliocaval Thrombosis Using a Protective Expandable Sheath,” Cardiovasc Intervent Radiol27-254-258, 2004, 5 pgs.
Turk et al., “ADAPT FAST study: a direct aspiration first pass technique for acute stroke thrombectomy.” J NeuroIntervent Surg, vol. 6, 2014, 6 pages.
Uflacker, R., “Interventional Therapy for Pulmonary Embolism”, Journal of Vascular and Interventional Radiology, Feb. 2001: 12:147-164.
Verma, R., MD et al. “Evaluation of a Newly Developed Percutaneous Thrombectomy Basket Device in Sheep With Central Pulmonary Embolisms”, Investigative Radiology, Oct. 2006, 41, 729-734.
International Search Report and Written Opinion for International App. No. PCT/US2015/034987 filed Jun. 9, 2015, Applicant: Inceptus Medical, LLC, dated Sep. 17, 2015, 12 pages.
English translation of Japanese Office Action received for JP Application No. 2016-564210, Applicant: Inceptus Medical, LLC, dated Sep. 4, 2017, 4 pages.
Australian Exam Report received for AU Application No. 2015274704, Applicant: Inceptus Medical, LLC, dated Sep. 7, 2017, 3 pages.
European Search Report received for EP Application No. 15805810.7, Applicant: Inceptus Medical, LLC, dated Sep. 4, 2017, 6 pages.
International Search Report and Written Opinion for International App. No. PCT/US2016/067628 filed Dec. 19, 2016, Applicant: Inari Medical, Inc., dated Apr. 10, 2017, 11 pages.
Goldhaber, S. et al. “Percutaneous Mechanical Thrombectomy for Acute Pulmonary Embolism—A Double-Edged Sword,” American College of CHEST Physicians, Aug. 2007, 132:2, 363-372.
Goldhaber, S., “Advanced treatment strategies for acute pulmonary embolism, including thrombolysis and embolectomy,” Journal of Thrombosis and Haemostasis, 2009: 7 (Suppl. 1): 322-327.
International Search Report and Written Opinion for International App. No. PCT/US2017/029696, Date of Filing: Apr. 26, 2017, Applicant: Inari Medical, Inc., dated Sep. 15, 2017, 19 pages.
International Search Report and Written Opinion for International App. No. PCT/US2016/058536, Date of Filing: Oct. 24, 2016, Applicant: Inari Medical, Inc., dated Mar. 13, 2017, 14 pages.
European First Office Action received for EP Application No. 13838945.7, Applicant: Inari Medical, Inc., dated Oct. 26, 2018, 7 pages.
International Search Report and Written Opinion for International App. No. PCT/US2018/048786, Date of Filing: Aug. 30, 2018, Applicant: Inari Medical, Inc., dated Dec. 13, 2018, 12 pages.
International Search Report and Written Opinion for International App. No. PCT/US2018/055780, Date of Filing: Oct. 13, 2018, Applicant: Inceptus Medical LLC., dated Jan. 22, 2019, 8 pages.
European Search Report for European Application No. 16876941.2, Date of Filing: Dec. 19, 2016, Applicant: Inari Medical, Inc., dated Jul. 18, 2019, 7 pages.
Extended European Search Report for European Application No. 16858462.1, Date of Filing: Oct. 24, 2016, Applicant: Inari Medical, Inc., dated Jun. 3, 2019, 10 pages.
International Search Report and Written Opinion for International App. No. PCT/US2019/045794, Date of Filing: Aug. 8, 2019, Applicant: Inari Medical, Inc., dated Nov. 1, 2019, 17 pages.
Partial Supplementary European Search Report for European Application No. 17864818.4, Date of Filing: May 21, 2019, Applicant: Inari Medical, Inc., dated Apr. 24, 2020, 11 pages.
International Search Report and Written Opinion for International App. No. PCT/US2020/056067, Date of Filing: Oct. 16, 2020; Applicant: Inari Medical, Inc., dated Jan. 22, 2021, 8 pages.
Extended European Search Report for European Application No. 20191581.6, Applicant: Inari Medical, Inc., dated Mar. 31, 2021, 11 pages.
International Search Report and Written Opinion for International App. No. PCT/US2020/055645, Date of Filing: Dec. 17, 2020; Applicant: Inari Medical, Inc., dated Apr. 14, 2021, 12 pages.
Extended European Search Report for European Application No. 18853465.5, Applicant: Inari Medical, Inc., dated May 7, 2021, 2021, 7 pages.
Vorwerk, D. MD, et al., “Use of a Temporary Caval Filter to Assist Percutaneous Iliocaval Thrombectomy Experimental Results.” SCVIR, 1995, 4 pages.
PCT International Search Report and Written Opinion for International Appln. No. PCT/US2020/014854, dated Oct. 5, 2020 (13 pages).
PCT International Search Report and Written Opinion for International Appln. No. PCT/US2020/018655, dated Dec. 16, 2020 (22 pages).
PCT International Search Report and Written Opinion for International Appln. No. PCT/US2020/017684, dated Nov. 30, 2020 (19 pages).
Extended European Search Report for EP Patent Appln. No. 20185092.2 dated Sep. 11, 2020, 6 pages.
EP Examination Report for EP Patent Appln. No. 18745794.0 dated Jul. 20, 2020, 4 pages.
Wikipedia; Embolectomy; retrieved from the internet: https://en.wikipedia.org/wiki/Embolectomy; 4 pgs.; retrieved/printed: Mar. 24, 2016.
O'Sullivan; Thrombolysis versus thrombectomy in acute deep vein thrombosis; Interventional Cardiology; 3(5); pp. 589-596; Oct. 2011.
Capture Vascular Systems; (company website); retrieved from the internet: http://www.capturevascular.com; 3 pgs.; retrieved/printed: Mar. 24, 2016.
Edwards Lifesciences; Fogarty® Occlusion Catheters (product brochure); retrieved from the internet: http://web.archive.org/web/20150228193218/http://www.edwards.com/products/vascular/atraumaticocclusion/pages/occlusioncatheter.aspx; © 2011; 2 pgs.; retrieved/printed: Mar. 24, 2011.
Boston Scientific; Fetch(TM) 2 Aspiration Catheter (product information);retrieved from the internet: http://www.bostonscientific.com/en-US/products/thrombectomy-systems/fetch2-aspiration-catheter.html; 2 pgs.; retrieved/printed: Mar. 24, 2016.
Penumbra, Inc.; Indigo® System (product information); retrieved from the internet: http://www.penumbrainc.com/peripherallpercutaneous-thromboembolectomy/indigo-system; 7 pgs.; retrieved/printed: Mar. 24, 2016.
YouTube; Merci Retrieval System X Series Animation; uploaded Mar. 16, 2009 (product information); posted on May 7, 2009 by SSMDePAUL, time 1:09, retrieved from the internet: https://www.youtube.com/watch?v=MGX7deuFkhc; 3 pgs.; retrieved/printed: Mar. 24, 2016.
Covidien; Solitaire(TM) AS Neurovascular Remodeling Device (product information); retrieved from the internet: http://www.ev3.net/neuro/intl/remodeling-devices/solitaire-ab. htm; © 2015; 2 pgs.; retrieved/printed: Mar. 24, 2016.
PCT International Search Report and Written Opinion for International Patent Appln. No. PCT/US2019/050467, Applicant Stryker Corporation, dated Dec. 18, 2019 (17 pages).
PCT International Search Report and Written Opinion for International Appln. No. PCT/US2017/029440, Applicant Stryker Corporation, dated Jul. 7, 2017.
PCT International Search Report and Written Opinion for International Appln. No. PCT/US2017/029472, Applicant Stryker Corporation, dated Jul. 7, 2017.
PCT International Search Report and Written Opinion for International Appln. No. PCT/US2017/035543, Applicant Stryker Corporation, dated Aug. 14, 2017.
PCT International Search Report and Written Opinion for International Appln. No. PCT/US2017/029366, Applicant Stryker Corporation, dated Aug. 29, 2017.
PCT International Search Report and Written Opinion for International Appln. No. PCT/US2017/050933, Applicant Stryker Corporation, forms PCT/ISA/210, 220, and 237, dated Nov. 10, 2017 (16 pages).
International search report and written opinion dated Feb. 28, 2018 for PCT/US2017/029345, Applicant Stryker Corporation 26 pages.
Extended European Search Report dated Aug. 22, 2018 for European patent appln No. 16852212.6, 6 pages.
Extended European Search Report dated Oct. 5, 2018 for European patent appln No. 18174891.4, 6 pages.
International search report and written opinion dated Nov. 14, 2018 for PCT/US2018/040937, Applicant Stryker Corporation 16 pages.
International Search Report and Written Opinion dated Mar. 28, 2019 for International Appln. No. PCT/US2018/059607.
International Search Report and Written Opinion dated May 6, 2016 for PCT/US2016/017982.
PCT International Search Report and Written Opinion for International Patent Appln. No. PCT/US2019/032601, Applicant Stryker Corporation, dated Jul. 23, 2019 (12 pages).
Extended European Search Report dated Oct. 8, 2019 for European Patent Application No. 19191925.7.
International Search Report and Written Opinion for International Patent Appln. No. PCT/US2019/050410 dated Oct. 25, 2019.
International Search Report and Written Opinion for International App. No. PCT/US21/35965, Date of Filing: Jun. 4, 2021, Applicant: Inari Medical, Inc., dated Sep. 28, 2021, 12 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/45072 Date of Filing: Aug. 6, 2021, Applicant: Inari Medical, Inc., dated Jan. 20, 2022, 10 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/58793; Date of Filing: Nov. 10, 2021, Applicant: Inari Medical, Inc., dated Mar. 16, 2022, 13 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/59718; Date of Filing: Nov. 17, 2021, Applicant: Inari Medical, Inc., dated Mar. 22, 2022, 13 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/59735; Date of Filing: Nov. 17, 2021, Applicant: Inari Medical, Inc., dated Mar. 22, 2022, 11 pages.
Related Publications (1)
Number Date Country
20210330344 A1 Oct 2021 US
Provisional Applications (2)
Number Date Country
61750277 Jan 2013 US
61728775 Nov 2012 US
Continuations (2)
Number Date Country
Parent 15949350 Apr 2018 US
Child 16913073 US
Parent 14646358 US
Child 15949350 US
Continuation in Parts (1)
Number Date Country
Parent 13843742 Mar 2013 US
Child 14646358 US